

# Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for treatment and follow-up

Annals of Oncology

29, iv192-iv237

DOI: [10.1093/annonc/mdy275](https://doi.org/10.1093/annonc/mdy275)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?. <i>Annals of Translational Medicine</i> , 2018, 6, S120-S120.	1.7	3
3	Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status. <i>OncoTargets and Therapy</i> , 2018, Volume 12, 15-19.	2.0	1
4	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e6.	3.9	20
5	Quelles stratÃ©gies thÃ©rapeutiques pour les CBNPC oligo-mÃ©tastatiques ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 326-331.	0.0	0
6	Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2053-2061.	1.1	52
7	Capmatinib for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 659-671.	2.4	64
8	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	2.4	42
9	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 1149-1160.	2.0	9
10	Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 831-840.	3.1	4
11	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 2423-2433.	2.4	73
12	Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. <i>Lung Cancer</i> , 2019, 136, 65-73.	2.0	8
13	Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital. <i>Cancers</i> , 2019, 11, 1196.	3.7	13
14	Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis. <i>Thoracic Cancer</i> , 2019, 10, 1819-1826.	1.9	8
15	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 135, 92-96.	2.0	22
16	Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2019, 135, 196-204.	2.0	81
17	LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY. <i>Cancer Research</i> , 2019, 79, 4453-4465.	0.9	24
18	Intra-individual variation of circulating tumour DNA in lung cancer patients. <i>Molecular Oncology</i> , 2019, 13, 2098-2106.	4.6	14
19	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	2.0	189

#	ARTICLE	IF	CITATIONS
20	Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. <i>Future Oncology</i> , 2019, 15, 2699-2706.	2.4	22
21	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. <i>BioDrugs</i> , 2019, 33, 555-570.	4.6	36
22	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. <i>Clinical Respiratory Journal</i> , 2019, 13, 590-597.	1.6	4
23	Importance of genetic screens in precision oncology. <i>ESMO Open</i> , 2019, 4, e000505.	4.5	10
24	Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S364-S368.	2.8	18
25	&lt;p&gt;Comparative review of drug&quot;drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5467-5484.	2.0	36
26	The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 727-738.	4.4	20
27	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	5.9	27
28	Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients. <i>PLoS ONE</i> , 2019, 14, e0219080.	2.5	1
29	The expanding role of endobronchial ultrasound in patients with centrally located intrapulmonary tumors. <i>Lung Cancer</i> , 2019, 134, 194-201.	2.0	9
31	Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4931.	4.1	44
32	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	10.7	418
33	What is the optimal radiotherapy utilization rate for lung cancer?&quot;a systematic review. <i>Translational Lung Cancer Research</i> , 2019, 8, S163-S171.	2.8	9
34	Phase II study of nab&quot;paclitaxel&quot;+&quot;carboplatin for patients with non&quot;small&quot;cell lung cancer and interstitial lung disease. <i>Cancer Science</i> , 2019, 110, 3738-3745.	3.9	49
35	Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031987789.	0.1	1
36	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. <i>Pathology</i> , 2019, 51, 673-680.	0.6	8
37	Definition of Synchronous Oligometastatic Non&quot;Small Cell Lung Cancer&quot;A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
38	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. <i>European Journal of Cancer</i> , 2019, 123, 28-35.	2.8	19

#	ARTICLE	IF	CITATIONS
39	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988553.	2.6	32
41	Bronchoscopic management of peripheral pulmonary lesions: robotic approach paves the way to the future. <i>BMC Pulmonary Medicine</i> , 2019, 19, 166.	2.0	7
42	Radical consolidative treatments a hope for patients with oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S1986-S1989.	1.4	1
43	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 3909-3919.	1.4	2
44	Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. <i>Journal of Thoracic Disease</i> , 2019, 11, S1847-S1851.	1.4	0
45	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	3.6	15
46	Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3895-3907.	2.4	10
47	Noncanonical Raf/p70S6K signalling in non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7632-7640.	3.6	8
48	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation. <i>Cancers</i> , 2019, 11, 1229.	3.7	23
49	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. <i>European Journal of Cancer</i> , 2019, 119, 77-86.	2.8	23
50	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019, 15, 3327-3336.	2.4	4
51	Treatment duration of checkpoint inhibitors for NSCLC. <i>Lancet Respiratory Medicine</i> , 2019, 7, 835-837.	10.7	6
52	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of $\geq 1\%$ by the USA Food and Drug Administration. <i>Annals of Oncology</i> , 2019, 30, 1686-1688.	1.2	20
53	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. <i>BMC Cancer</i> , 2019, 19, 896.	2.6	33
55	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6644-6652.	7.0	100
56	Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 80, 101892.	7.7	45
57	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	3.2	27
58	Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6481-6495.	2.0	4

#	ARTICLE	IF	CITATIONS
59	Lung Cancer in Slovenia. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1327-1331.	1.1	7
60	Changing equipoise in the landscape of radiation for oligometastatic lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S184-S191.	2.8	2
61	New options for combination therapy for advanced non-squamous NSCLC. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1095-1107.	2.5	15
62	Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. <i>Annals of Oncology</i> , 2019, 30, 1660-1666.	1.2	63
63	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	3.7	7
64	Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 725-737.	6.4	702
65	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 546-549.	2.8	3
66	A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 136-143.	2.0	8
67	Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 137, 113-122.	2.0	154
68	Programmed cell death protein receptor and ligands in haematological malignancies â€œ Current status. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 47-58.	4.4	4
69	Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?. <i>Immunotherapy</i> , 2019, 11, 161-166.	2.0	5
70	Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?. <i>Lung Cancer</i> , 2019, 129, 95-97.	2.0	3
71	Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2019, 11, 407-428.	2.0	53
72	Meta-analysis comparing incidence of grade 3â€“4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2163-2174.	2.4	2
73	Emerging angiogenesis inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 71-81.	2.4	10
74	Muscle derangement and alteration of the nutritional machinery in NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 43-53.	4.4	14
75	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 116, 182-189.	2.8	36
76	Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. , 2019, 202, 140-148.		43

#	ARTICLE	IF	CITATIONS
77	Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0218414.	2.5	9
78	Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands. Lung Cancer, 2019, 134, 34-41.	2.0	13
79	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1134-1155.	1.1	61
80	Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC: A retrospective cohort study. Lung Cancer, 2019, 134, 59-65.	2.0	31
81	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 222.	8.6	45
82	Current status of immune checkpoint inhibition in early-stage NSCLC. Annals of Oncology, 2019, 30, 1244-1253.	1.2	98
83	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 2019, 37, 2518-2527.	1.6	811
84	Alternative splicing in lung cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 194388.	1.9	47
85	Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2071-2082.	2.5	27
86	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer, 2019, 134, 127-140.	2.0	156
87	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opinion on Investigational Drugs, 2019, 28, 513-523.	4.1	21
88	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 561-568.	2.4	58
89	Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, 2019, 15, 2287-2302.	2.4	42
90	ESMO 2018 personal highlights. Memo - Magazine of European Medical Oncology, 2019, 12, 67-70.	0.5	0
91	Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 531-542.	3.8	210
92	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	10.7	1,133
93	Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncologica, 2019, 58, 953-961.	1.8	35
94	It's far better to be alone than to be in bad company. Journal of Thoracic Disease, 2019, 11, 649-651.	1.4	1

#	ARTICLE	IF	CITATIONS
95	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	2.0	2
96	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	1.1	324
97	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
98	PD(L)1 inhibitors vs chemotherapy vs their combination in front-line treatment for NSCLC: An indirect comparison. International Journal of Cancer, 2019, 145, 3011-3021.	5.1	15
99	Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance. Memo - Magazine of European Medical Oncology, 2019, 12, 128-135.	0.5	1
100	Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice. Archivos De Bronconeumologia, 2019, 55, 289-290.	0.8	1
101	A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. Current Oncology, 2019, 26, 241-254.	2.2	34
102	Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncology, 2019, 15, 1493-1504.	2.4	6
103	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer – Just About Ready for Prime-Time?. Cancers, 2019, 11, 283.	3.7	86
104	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896.	1.2	78
105	I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncology, 2019, 15, 1551-1563.	2.4	16
106	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology, 2019, 14, 933-939.	1.1	152
107	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine, 2019, 13, 435-447.	2.5	7
108	Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study. European Journal of Cancer Care, 2019, 28, e13034.	1.5	3
109	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis, 2019, 22, 433-440.	7.2	28
110	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. Journal of Translational Medicine, 2019, 17, 99.	4.4	52
111	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine, the, 2019, 7, 387-401.	10.7	704
112	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer, 2019, 132, 17-23.	2.0	12



#	ARTICLE	IF	CITATIONS
113	Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. Lung Cancer, 2019, 130, 67-75.	2.0	40
114	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clinical and Translational Oncology, 2019, 21, 1270-1279.	2.4	38
115	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383.	2.4	10
116	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. Expert Opinion on Biological Therapy, 2019, 19, 457-467.	3.1	7
117	From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO Open, 2019, 4, e000548.	4.5	22
118	A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group. Journal of Thoracic Disease, 2019, 11, 5635-5642.	1.4	0
119	Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. Translational Cancer Research, 2019, 8, S612-S617.	1.0	10
120	<p>Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Smallâ€Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)</p>. Cancer Management and Research, 2019, Volume 11, 10821-10826.	1.9	0
121	Targeting BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 1119-1124.	2.8	65
122	The electronic nose: emerging biomarkers in lung cancer diagnostics. Breathe, 2019, 15, e135-e141.	1.3	15
123	Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, S383-S386.	2.8	4
124	Accelerating the development of therapeutic strategy for oligometastasis. Journal of Thoracic Disease, 2019, 11, 5670-5673.	1.4	1
125	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 989-999.	2.8	28
126	ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 2019, 138, 13-18.	2.0	8
127	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. The Cochrane Library, 0, , .	2.8	2
128	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. Targeted Oncology, 2019, 14, 759-768.	3.6	21
129	Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open, 2019, 4, e000477.	4.5	25
130	Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients. Scientific Reports, 2019, 9, 19872.	3.3	8



#	ARTICLE	IF	CITATIONS
131	Prise en charge des métastases osseuses des cancers broncho-pulmonaires non petites cellules. Revue Des Maladies Respiratoires Actualites, 2019, 11, 392-404.	0.0	0
132	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers, 2019, 11, 1893.	3.7	7
133	Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer. Frontiers in Genetics, 2019, 10, 1008.	2.3	23
134	OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase. Scientific Reports, 2019, 9, 18101.	3.3	10
135	Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 107.	4.0	38
136	Plasma-thrombin cell blocks: Potential source of DNA contamination. Cancer Cytopathology, 2019, 127, 771-777.	2.4	7
137	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	3.2	28
138	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 921-930.	2.0	8
139	Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway. OncoTargets and Therapy, 2019, Volume 12, 9355-9365.	2.0	30
140	Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy, 2019, 11, 1445-1461.	2.0	37
141	Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer. Medicine (United States), 2019, 98, e17705.	1.0	4
142	Diagnosis and characterization of malignant effusions through pleural fluid cytological examination. Current Opinion in Pulmonary Medicine, 2019, 25, 362-368.	2.6	22
143	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30, 171-210.	1.2	214
144	Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. Clinical and Translational Oncology, 2019, 21, 790-795.	2.4	22
145	The role of circulating free DNA in the management of NSCLC. Expert Review of Anticancer Therapy, 2019, 19, 19-28.	2.4	20
146	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
147	Cáncer de pulmón y biopsia líquida: realidades y retos en la práctica clínica. Archivos De Bronconeumología, 2019, 55, 289-290.	0.8	5
148	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	2.6	40

#	ARTICLE	IF	CITATIONS
149	Mutational profile of non-small cell lung cancer patients: Use of next-generation sequencing. <i>Pulmonology</i> , 2020, 26, 50-53.	2.1	3
150	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 854-861.	1.2	64
151	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	2.6	24
152	Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France). <i>Clinical Lung Cancer</i> , 2020, 21, 56-65.e8.	2.6	23
153	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	2.4	11
154	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-Small-Cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	2.6	19
155	Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 48-53.	2.1	3
156	Exploiting metabolic vulnerabilities of Non small cell lung carcinoma. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 54-62.	5.0	36
157	Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study. <i>International Journal of Cancer</i> , 2020, 146, 2510-2517.	5.1	14
158	The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. <i>Current Clinical Pharmacology</i> , 2020, 15, 11-19.	0.6	14
159	Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102820.	4.4	53
160	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	2.4	59
161	Impact of different metal artifact reduction techniques on attenuation correction in 18F-FDG PET/CT examinations. <i>British Journal of Radiology</i> , 2020, 93, 20190069.	2.2	9
162	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. <i>Lancet Oncology</i> , The, 2020, 21, e18-e28.	10.7	588
163	Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1321-1328.	2.4	11
164	DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma. <i>Biochemical Pharmacology</i> , 2020, 172, 113772.	4.4	17
165	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020, 140, 71-79.	2.0	8
166	Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 218-228.	1.3	10

#	ARTICLE	IF	CITATIONS
167	Imaging Features and Metastatic Patterns of Advanced <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer. American Journal of Roentgenology, 2020, 214, 766-774.	2.2	15
168	Twenty-five years of <i>Respirology</i> : Advances in lung cancer. Respirology, 2020, 25, 26-31.	2.3	2
169	Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Cancer Biomarkers, 2020, 27, 313-323.	1.7	2
170	Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. Neurology, 2020, 94, e521-e528.	1.1	40
171	External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. Journal of Pathology: Clinical Research, 2020, 6, 138-145.	3.0	22
172	Comparability of PD-L1 immunohistochemistry assays for non-small cell lung cancer: a systematic review. Histopathology, 2020, 76, 793-802.	2.9	34
173	Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. Current Opinion in Oncology, 2020, 32, 44-53.	2.4	18
174	Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	27.0	1,725
175	Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clinical and Experimental Metastasis, 2020, 37, 199-207.	3.3	24
176	Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. Oncologist, 2020, 25, e598-e601.	3.7	18
177	Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Pharmacogenomics Journal, 2020, 20, 380-387.	2.0	7
178	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2020, 10, 765.	2.6	7
179	The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF- $\kappa$ B Pathway in Non-Small Cell Lung Cancer. OncoTargets and Therapy, 2020, Volume 13, 10707-10719.	2.0	5
180	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. Cancers, 2020, 12, 2658.	3.7	10
181	Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience. Lung Cancer, 2020, 149, 5-9.	2.0	22
183	KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/ $\beta$ -catenin signaling pathway. Life Sciences, 2020, 262, 118508.	4.3	17
184	Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an <i>STK11</i> / <i>LKB1</i> Mutation. JCO Precision Oncology, 2020, 4, 1239-1245.	3.0	13
185	Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies. ESMO Open, 2020, 5, e000867.	4.5	13

#	ARTICLE	IF	CITATIONS
186	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
188	Microsatellite Instability Testing and Therapy Implications. <i>Advances in Molecular Pathology</i> , 2020, 3, 169-188.	0.4	4
189	cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?. <i>EBioMedicine</i> , 2020, 57, 102886.	6.1	1
190	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	2.8	47
191	Traitement des cancers bronchiques non À petites cellules de stades avancÃ©s mutÃ©s EGFR : quels inhibiteurs ? Quelles sÃ©quences thÃ©rapeutiques ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S195-2S211.	0.0	2
192	Prise en charge des mÃ©tastases osseuses des cancers broncho-pulmonaires non À petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S223-2S232.	0.0	0
195	Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC. <i>Lung Cancer</i> , 2020, 149, 144-153.	2.0	0
196	CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas. <i>Scientific Reports</i> , 2020, 10, 16251.	3.3	5
197	Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). <i>ESMO Open</i> , 2020, 5, e000656.	4.5	4
198	Pearls and pitfalls in lung cancer staging. <i>BJR   Open</i> , 2020, 2, 20200019.	0.6	1
199	Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3287-3295.	1.4	9
200	Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. <i>Frontiers in Immunology</i> , 2020, 11, 1479.	4.8	30
201	Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand. <i>BMC Cancer</i> , 2020, 20, 658.	2.6	8
202	Lung cancer biomarker testing: perspective from Europe. <i>Translational Lung Cancer Research</i> , 2020, 9, 887-897.	2.8	25
203	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IMS/MS Assay. <i>Cancers</i> , 2020, 12, 1897.	3.7	14
204	Quantitative Preferences for Lung Cancer TreatmentÂfrom theÂPatientsâ€™ Perspective: A Systematic Review. <i>Patient</i> , 2020, 13, 521-536.	2.7	14
205	Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series. <i>Scientific Reports</i> , 2020, 10, 11201.	3.3	7
206	Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 509297.	2.8	3

#	ARTICLE	IF	CITATIONS
207	Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial. <i>Cancers</i> , 2020, 12, 3359.	3.7	3
208	Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550002.	2.8	10
209	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. <i>Cancers</i> , 2020, 12, 3459.	3.7	11
210	Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 2514.	4.1	18
211	Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. <i>BMJ Open</i> , 2020, 10, e040691.	1.9	7
212	Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 1-11.	2.0	68
213	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 743-753.	2.4	1
214	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. <i>British Journal of Cancer</i> , 2020, 123, 874-884.	6.4	15
215	A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. <i>Cancer Cytopathology</i> , 2020, 128, 928-938.	2.4	13
216	Precision medicine in non-small cell lung cancer: Current applications and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 184-198.	9.6	106
217	KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. <i>European Journal of Cancer</i> , 2020, 137, 57-68.	2.8	30
218	Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522094638.	0.9	0
219	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6885-6896.	2.0	1
220	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	4.4	17
221	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. <i>Drugs and Aging</i> , 2020, 37, 677-689.	2.7	1
222	Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2273.	2.4	3
223	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
224	Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1179-1194.	1.4	1

#	ARTICLE	IF	CITATIONS
225	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , 2020, 9, 2337.	4.1	13
226	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	3.7	10
227	Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective. <i>Journal of Clinical Medicine</i> , 2020, 9, 3483.	2.4	26
228	New chalcone-tethered 1,3,5-triazines potentiate the anticancer effect of cisplatin against human lung adenocarcinoma A549 cells by enhancing DNA damage and cell apoptosis. <i>Bioorganic Chemistry</i> , 2020, 105, 104393.	4.1	26
229	Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000505.	3.0	1
230	Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. <i>Future Oncology</i> , 2020, 16, 3107-3116.	2.4	5
231	Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. <i>Journal of Medical Economics</i> , 2020, 23, 1330-1339.	2.1	11
232	EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India. <i>Cancer Reports</i> , 2020, 3, e1288.	1.4	3
233	Accuracy of lung cancer staging in the multidisciplinary team setting. <i>Translational Lung Cancer Research</i> , 2020, 9, 1654-1666.	2.8	15
234	EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095373.	3.2	8
235	Non-interventional LUME-BionIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. <i>Lung Cancer</i> , 2020, 148, 159-165.	2.0	17
236	Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression. <i>Lung Cancer</i> , 2020, 149, 23-32.	2.0	13
237	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	27.0	1,042
238	Adoptive transfer of zoledronate-expanded autologous V $\beta$ 9V $\alpha$ 2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. , 2020, 8, e001185.		22
239	Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1225-1234.	2.8	14
240	Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. <i>BMC Cancer</i> , 2020, 20, 806.	2.6	12
241	The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease. <i>Radiation Oncology</i> , 2020, 15, 207.	2.7	16
242	Cellular retinol binding protein 1 transfection reduces proliferation and AKT-related gene expression in H460 non-small lung cancer cells. <i>Molecular Biology Reports</i> , 2020, 47, 6879-6886.	2.3	6



#	ARTICLE	IF	CITATIONS
243	Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulmonary Medicine, 2020, 20, 240.	2.0	16
244	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO Open, 2020, 5, e000753.	4.5	25
245	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
246	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091380.	3.2	10
247	Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study. Journal of International Medical Research, 2020, 48, 030006052093709.	1.0	0
248	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Current Medical Research and Opinion, 2020, 36, 1667-1675.	1.9	11
249	Lung Cancer in Lithuania. Journal of Thoracic Oncology, 2020, 15, 1401-1405.	1.1	0
250	Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. OncoTargets and Therapy, 2020, Volume 13, 12539-12547.	2.0	3
251	Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096723.	3.2	13
252	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals, 2020, 13, 474.	3.8	51
253	Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers, 2020, 12, 3729.	3.7	55
254	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. JTO Clinical and Research Reports, 2020, 1, 100068.	1.1	10
255	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	2.6	18
256	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095480.	3.2	9
257	Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. Cancer Management and Research, 2020, Volume 12, 12593-12602.	1.9	11
258	Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. Cancers, 2020, 12, 3668.	3.7	13
259	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. Diagnostics, 2020, 10, 902.	2.6	1
260	Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. Translational Lung Cancer Research, 2020, 9, 1736-1748.	2.8	9



#	ARTICLE	IF	CITATIONS
261	Pulmonary enteric adenocarcinoma: an overview. Expert Reviews in Molecular Medicine, 2020, 22, e1.	3.9	11
262	Combination treatments with immunotherapy in brain metastases patients. Future Oncology, 2020, 16, 1691-1705.	2.4	2
263	Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology, 2020, 31, 1056-1064.	1.2	337
264	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung Cancer, 2020, 144, 76-84.	2.0	29
265	LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 656.	2.8	25
266	Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology, 2020, 9, 1744898.	4.6	27
267	Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2051-2066.	2.5	67
268	Immune Checkpoint Inhibitor-Associated Myocarditis. JACC: Case Reports, 2020, 2, 630-635.	0.6	6
269	Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. Thoracic Cancer, 2020, 11, 1911-1917.	1.9	13
270	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlook 8. 1132-1143.	10.7	169
271	A BRAF new world. Critical Reviews in Oncology/Hematology, 2020, 152, 103008.	4.4	39
272	A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing. Lung Cancer, 2020, 146, 387-388.	2.0	0
273	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2530-2542.	1.6	47
274	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE, 2020, 15, e0234302.	2.5	13
275	Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2277-2287.	2.5	11
276	Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. Drug Discovery Today, 2020, 25, 1580-1584.	6.4	3
277	Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. Anti-Cancer Drugs, 2020, 31, 310-313.	1.4	2
278	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. Diagnostics, 2020, 10, 359.	2.6	51

#	ARTICLE	IF	CITATIONS
279	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	2.6	29
280	PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 83-87.	1.7	7
281	Electrolyte Disorders Induced by Antineoplastic Drugs. Frontiers in Oncology, 2020, 10, 779.	2.8	39
282	Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. Frontiers in Cell and Developmental Biology, 2020, 8, 370.	3.7	6
283	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. Oncologist, 2020, 25, e1996-e2005.	3.7	21
284	Lorlatinib for the treatment of <i>ALK</i>-positive metastatic non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 233-240.	2.4	12
285	<b>Ethnic Disparities inÂ</b>Imaging<b>Utilization at Diagnosis of Non-Small Cell Lung Cancer</b>. Journal of the National Cancer Institute, 2020, 112, 1204-1212.	6.3	27
286	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of Oncology, 2020, 31, 507-516.	1.2	289
287	EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Nonâ€“Small-cell Lung Cancer Treated With Immunotherapy. Clinical Lung Cancer, 2020, 21, 365-377.e5.	2.6	44
288	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. Journal of Thoracic Oncology, 2020, 15, 1015-1026.	1.1	58
289	Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements. Cancers, 2020, 12, 693.	3.7	16
290	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. European Radiology, 2020, 30, 4496-4503.	4.5	7
291	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Advances in Therapy, 2020, 37, 2116-2126.	2.9	24
292	Constructing an E-Nose Using Metal-Ion-Induced Assembly of Graphene Oxide for Diagnosis of Lung Cancer via Exhaled Breath. ACS Applied Materials & Interfaces, 2020, 12, 17713-17724.	8.0	66
293	Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 2020, 12, 731.	3.7	280
294	First-line pembrolizumab in advanced nonâ€“small cell lung cancer patients with poor performance status. European Journal of Cancer, 2020, 130, 155-167.	2.8	98
295	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2020, 14, 565-576.	2.5	9
296	Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey. JCO Oncology Practice, 2020, 16, e770-e778.	2.9	7

#	ARTICLE	IF	CITATIONS
297	Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662091009.	2.6	8
298	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	2.4	7
299	Combination of Immunotherapy and Radiotherapyâ€”The Next Magic Step in the Management of Lung Cancer?. Journal of Thoracic Oncology, 2020, 15, 166-169.	1.1	10
300	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€” A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035.	4.4	5
301	Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial. Frontiers in Oncology, 2020, 10, 890.	2.8	5
302	Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT). Cancers, 2020, 12, 1627.	3.7	10
303	Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?. Clinical Oncology, 2020, 32, 674-684.	1.4	9
304	A reply to â€œA modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencingâ€. Lung Cancer, 2020, 146, 389-390.	2.0	0
305	PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2093.	2.4	13
306	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. Journal of Thoracic Disease, 2020, 12, 2771-2780.	1.4	13
307	Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology, 2020, 153, 102948.	4.4	21
308	&lt;p&gt;Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 4453-4460.	1.9	6
309	Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies, 2020, 20, 3.	2.7	14
310	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	3.5	3
311	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	2.8	112
312	Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis. European Journal of Cardio-thoracic Surgery, 2020, 57, 1166-1172.	1.4	33
313	Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. European Respiratory Journal, 2020, 55, 1901907.	6.7	27
314	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology, 2019, 9, 1550.	2.8	26

#	ARTICLE	IF	CITATIONS
315	Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution. <i>Journal of Translational Medicine</i> , 2020, 18, 87.	4.4	8
316	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
317	Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. <i>Scientific Reports</i> , 2020, 10, 3625.	3.3	41
318	Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 363-372.	4.1	13
319	Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 183-193.	2.0	7
320	The force of HER2 – A druggable target in NSCLC?. <i>Cancer Treatment Reviews</i> , 2020, 86, 101996.	7.7	46
321	Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102906.	4.4	43
322	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	4.4	42
323	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	2.4	4
324	Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. <i>Advances in Therapy</i> , 2020, 37, 946-954.	2.9	15
325	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 373-386.	10.7	300
326	Cytology for PD-L1 testing: A systematic review. <i>Lung Cancer</i> , 2020, 141, 101-106.	2.0	42
327	Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. <i>European Journal of Cancer Care</i> , 2020, 29, e13206.	1.5	3
328	Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity. <i>Frontiers in Oncology</i> , 2020, 9, 1521.	2.8	11
329	Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. <i>JCO Precision Oncology</i> , 2020, 4, 393-410.	3.0	32
330	Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program. <i>Future Oncology</i> , 2020, 16, 1031-1041.	2.4	7
331	EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 356.	2.6	33
332	Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e464-e473.	2.6	24

#	ARTICLE	IF	CITATIONS
333	Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 856.	7.1	103
334	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European Journal of Cancer, 2020, 131, 27-36.	2.8	44
335	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 947.	3.7	20
336	Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naïve Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France). Cancers, 2020, 12, 955.	3.7	16
337	Recognition of breathprints of lung cancer and chronic obstructive pulmonary disease using the Aeonose <sup>®</sup> electronic nose. Journal of Breath Research, 2020, 14, 046004.	3.0	17
338	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. European Journal of Health Economics, 2020, 21, 931-943.	2.8	7
339	Is tissue still the issue in detecting molecular alterations in lung cancer?. Respiriology, 2020, 25, 933-943.	2.3	31
340	Causation between Pathway Completion and Reduced Hospital Stay in Patients with Lung Cancer: a Retrospective Cohort Study Using Propensity Score Matching. Journal of Medical Systems, 2020, 44, 105.	3.6	2
341	Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. Lung Cancer Management, 2020, 9, LMT28.	1.5	3
342	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. Journal of Thoracic Oncology, 2020, 15, 1351-1360.	1.1	379
343	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. European Radiology, 2020, 30, 5021-5028.	4.5	10
344	Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2020, 21, 1287-1298.	1.8	12
345	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials, 2020, 21, 352.	1.6	7
346	Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis. BMC Cancer, 2020, 20, 260.	2.6	33
347	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2020, 4, 272-282.	3.0	36
348	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. Current Oncology, 2020, 27, 52-60.	2.2	13
349	Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review. Supportive Care in Cancer, 2021, 29, 445-457.	2.2	20
350	Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. Clinical Pharmacokinetics, 2021, 60, 69-77.	3.5	12

#	ARTICLE	IF	CITATIONS
351	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	2.0	53
352	Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 415-423.	1.4	8
353	Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial. Supportive Care in Cancer, 2021, 29, 1629-1633.	2.2	7
354	Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines. Integrative Medicine Research, 2021, 10, 100452.	1.8	12
355	Commentary: Extended disease, but still not the end for patients. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1507-1508.	0.8	0
356	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	7.0	50
357	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Investigational New Drugs, 2021, 39, 477-487.	2.6	41
358	Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naïve Lung Cancer: A Meta-Analysis. Clinical Lung Cancer, 2021, 22, e70-e83.	2.6	10
359	Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer, 2021, 151, 60-68.	2.0	19
360	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
361	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	7.4	16
362	Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. Drugs, 2021, 81, 87-100.	10.9	13
363	The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib. Targeted Oncology, 2021, 16, 77-84.	3.6	8
364	Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients. Journal of Neuro-Oncology, 2021, 151, 257-265.	2.9	9
365	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clinical Lung Cancer, 2021, 22, e180-e192.	2.6	15
366	Proposing synchronous oligometastatic non-small cell lung cancer based on progression after first-line systemic therapy. Cancer Science, 2021, 112, 359-368.	3.9	10
367	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical and Translational Oncology, 2021, 23, 1304-1313.	2.4	4
368	The development of small-molecule inhibitors targeting CD47. Drug Discovery Today, 2021, 26, 561-568.	6.4	44



#	ARTICLE	IF	CITATIONS
369	Suppression of tumor immune microenvironment via microRNAâ€1 after epidermal growth factor receptorâ€tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 718-727.	2.8	11
370	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 653-664.	1.1	251
371	Molecular profiling of longâ€term responders to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	4.6	24
372	Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Nonâ€Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome. <i>Clinical Lung Cancer</i> , 2021, 22, e220-e223.	2.6	2
373	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40
374	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. <i>Oncologist</i> , 2021, 26, e306-e315.	3.7	24
376	Comparison of the analytical performance between the <scp>O</scp>ncome <scp>D</scp>x <scp>T</scp>arget <scp>T</scp>est and a conventional single gene test for epidermal growth factor receptor mutation in nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 462-467.	1.9	10
377	Formalin fixation for optimal concordance of programmed deathâ€ligand 1 immunostaining between cytologic and histologic specimens from patients with nonâ€small cell lung cancer. <i>Cancer Cytopathology</i> , 2021, 129, 304-317.	2.4	13
378	Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 333-354.	5.0	17
379	Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. <i>Future Oncology</i> , 2021, 17, 471-486.	2.4	11
380	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 73-102.	5.0	13
381	Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus â€at progressionâ€cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	3.2	2
382	Diagnosis and Molecular Profiling of Lung Cancer by Percutaneous Ultrasound-Guided Biopsy of Superficial Metastatic Sites Is Safe and Highly Effective. <i>Respiration</i> , 2021, 100, 515-522.	2.6	6
383	How to handle oligometastatic disease in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200234.	7.1	2
384	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 36.	0.2	0
385	Tumors: Non-small Cell Lung Cancer. , 2021, , 1-10.		0
386	Successful treatment with crizotinib after alectinib-induced interstitial lung disease. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110429.	0.3	4
387	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	3.2	2



#	ARTICLE	IF	CITATIONS
388	Surgical Survival Benefits With Different Metastatic Patterns for Stage IV Extrathoracic Metastatic Non-Small Cell Lung Cancer: A SEER-Based Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110330.	1.9	5
389	Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100404.	1.7	6
390	Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 869-876.	1.1	19
391	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. <i>Cell Death and Disease</i> , 2021, 12, 106.	6.3	16
392	Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Korean Journal of Radiology</i> , 2021, 22, 2082.	3.4	6
393	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	2.8	29
394	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncolimmunology</i> , 2021, 10, 1957603.	4.6	10
395	Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 607-621.	2.8	9
396	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the â€”TOASTâ€” database. <i>Radiation Oncology</i> , 2021, 16, 4.	2.7	20
397	Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. <i>Journal of Medical Economics</i> , 2021, 24, 328-338.	2.1	0
398	Antiproliferative Activity and Potential Mechanism of Marine-Sourced Streptoglutaramide H against Lung Cancer Cells. <i>Marine Drugs</i> , 2021, 19, 79.	4.6	9
399	A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Molecular Pathology</i> , 2021, 2, 1-10.	1.2	5
400	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 649-654.	3.5	7
401	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100378.	1.7	8
402	Induction treatment in patients with stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 539-554.	2.8	8
403	Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Nonâ€”Small Cell Lung Cancer from the PACIFIC Study. <i>Current Therapeutic Research</i> , 2021, 95, 100640.	1.2	1
404	MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinomaâ€”Current Understanding and Therapeutic Advances. <i>Oncology &amp; Hematology Review</i> , 2021, 16, 100.	0.2	2
405	<sup>18</sup> F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions. <i>Journal of Cancer</i> , 2021, 12, 562-570.	2.5	2

#	ARTICLE	IF	CITATIONS
406	2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology. Korean Journal of Radiology, 2021, 22, 263.	3.4	31
407	Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions. Frontiers in Medicine, 2020, 7, 562480.	2.6	6
408	RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 2418-2425.	3.6	16
409	The influence of genetic polymorphisms on the toxicity of platinum-based chemotherapy in the treatment of non-small cell lung cancer. Medicinski Podmladak, 2021, 72, 40-47.	0.0	0
410	OUP accepted manuscript. Radiation Protection Dosimetry, 2021, 196, 190-198.	0.8	1
411	Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents. Supportive Care in Cancer, 2021, 29, 4081-4088.	2.2	2
412	The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 855-865.	2.8	7
413	Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study. Cancer Science, 2021, 112, 1556-1566.	3.9	12
414	Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy. Frontiers in Molecular Biosciences, 2021, 8, 630718.	3.5	21
415	IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Science, 2021, 112, 1534-1544.	3.9	24
416	Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. ESMO Open, 2021, 6, 100045.	4.5	18
417	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 699-711.	2.8	12
418	Challenges of diagnostic genomics in Latin America. Current Opinion in Genetics and Development, 2021, 66, 101-109.	3.3	13
419	Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). JTO Clinical and Research Reports, 2021, 2, 100104.	1.1	4
420	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	3.7	38
421	Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients. Frontiers in Public Health, 2021, 9, 622154.	2.7	9
422	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. ESMO Open, 2021, 6, 100013.	4.5	2
423	Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations. Translational Lung Cancer Research, 2021, 10, 753-765.	2.8	17

#	ARTICLE	IF	CITATIONS
424	A PET/CT nomogram incorporating SUVmax and CT radiomics for preoperative nodal staging in non-small cell lung cancer. <i>European Radiology</i> , 2021, 31, 6030-6038.	4.5	24
425	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 878-888.	2.8	4
426	Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status. <i>BMC Cancer</i> , 2021, 21, 132.	2.6	6
427	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. <i>Lung Cancer</i> , 2021, 152, 119-126.	2.0	17
428	The value of endobronchial ultrasound-guided transbronchial needle aspiration, 18-fluorodeoxyglucose positron emission tomography/computed tomography, and ultrasonography imaging techniques in the diagnosis of mediastinal and/or hilar malignant, anthracotic, and other benign lymph nodes. <i>Medicine (United States)</i> , 2021, 100, e24728.	1.0	4
429	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Cancers</i> , 2021, 13, 804.	3.7	76
430	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142.	1.1	1
431	A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). <i>Frontiers in Pharmacology</i> , 2021, 12, 599598.	3.5	10
432	Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 673-679.	2.4	6
433	Letter to the Editor. <i>Lung Cancer</i> , 2021, 153, 184.	2.0	0
434	A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1536-1556.	2.8	28
435	Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development. <i>Translational Lung Cancer Research</i> , 2021, 10, 1444-1456.	2.8	6
436	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
437	Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice. <i>Diagnostics</i> , 2021, 11, 512.	2.6	3
438	A Retrospective Analysis of the Palliative Surgical Treatment in Patients with Malignant Pleural Effusion. <i>Acta Medica Martiniana</i> , 2021, 21, 13-20.	0.3	0
439	Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. <i>PLoS ONE</i> , 2021, 16, e0247620.	2.5	43
440	Meningeal â€œLazarus Responseâ€ to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 2805-2810.	1.9	5
441	Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients. <i>Tumori</i> , 2022, 108, 86-92.	1.1	5

#	ARTICLE	IF	CITATIONS
442	Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. <i>Trials</i> , 2021, 22, 214.	1.6	1
443	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. <i>Advances in Therapy</i> , 2021, 38, 2038-2053.	2.9	8
444	Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. <i>Drugs - Real World Outcomes</i> , 2021, 8, 141-152.	1.6	6
445	A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021, 21, 208.	2.6	13
446	MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C. <i>Oncology Letters</i> , 2021, 21, 389.	1.8	5
447	Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP). <i>Journal of Clinical Pathology</i> , 2022, 75, 193-200.	2.0	12
448	What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences. <i>Frontiers in Pharmacology</i> , 2021, 12, 602112.	3.5	6
449	Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay. <i>Oncologist</i> , 2021, 26, e908-e912.	3.7	6
450	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.	2.4	13
451	Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. <i>Anti-Cancer Drugs</i> , 2021, 32, 758-762.	1.4	9
452	Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR. <i>Translational Lung Cancer Research</i> , 2021, 10, 1200-1208.	2.8	14
453	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	2.8	29
454	Routine Molecular Screening of Patients with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 239-250.	3.8	6
455	Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. <i>Nature Communications</i> , 2021, 12, 1628.	12.8	103
456	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD010383.	2.8	28
457	Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 1222.	3.7	8
458	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). <i>BioDrugs</i> , 2021, 35, 429-444.	4.6	15
459	The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. <i>ESMO Open</i> , 2021, 6, 100087.	4.5	18

#	ARTICLE	IF	CITATIONS
460	Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. <i>Cancer Treatment Reviews</i> , 2021, 95, 102173.	7.7	14
461	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. <i>ESMO Open</i> , 2021, 6, 100051.	4.5	11
462	Molecular diagnosis in non-small-cell lung cancer: expert opinion on <i>ALK</i> and <i>ROS1</i> testing. <i>Journal of Clinical Pathology</i> , 2022, 75, 145-153.	2.0	26
463	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. <i>Cancers</i> , 2021, 13, 2132.	3.7	5
464	EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2084.	3.7	21
465	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. <i>Annals of Translational Medicine</i> , 2021, 9, 648-648.	1.7	2
466	Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4403.	4.1	24
467	Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System. <i>Frontiers in Pharmacology</i> , 2021, 12, 657743.	3.5	13
468	Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 637804.	2.8	10
469	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103305.	4.4	25
470	The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis. <i>Lung Cancer</i> , 2021, 154, 62-68.	2.0	3
471	An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection. <i>Clinical Chemistry</i> , 2021, 67, 959-967.	3.2	7
472	Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 551-551.	1.7	5
473	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. <i>Genes</i> , 2021, 12, 679.	2.4	25
474	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	2.0	8
475	Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. <i>Scientific Reports</i> , 2021, 11, 9222.	3.3	35
476	Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India. <i>JCO Global Oncology</i> , 2021, 7, 593-601.	1.8	12
478	High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	4.1	37

#	ARTICLE	IF	CITATIONS
479	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.	2.8	10
480	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	2.0	25
481	Evolution of systemic therapy for stages Iâ€“III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	27.6	152
482	Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25992.	1.0	5
483	Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. <i>Targeted Oncology</i> , 2021, 16, 339-355.	3.6	6
484	<scp><i>ALK</i></scp>â€“positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved longâ€“term survival of more than seven years with sequential treatment of five <scp>ALK</scp>â€“inhibitors: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1761-1764.	1.9	4
485	Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 632256.	2.8	9
486	PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. <i>Tumori</i> , 2022, 108, 47-55.	1.1	8
487	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	2.8	0
488	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 807-816.	1.1	11
489	Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 39, 127915.	2.2	3
490	The emerging role of local therapy in oligometastatic nonâ€“small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 819-825.	0.8	7
491	Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4852.	4.1	17
492	Unveiling mutational dynamics in nonâ€“small cell lung cancer patients by quantitative <i>EGFR</i> profiling in vesicular RNA. <i>Molecular Oncology</i> , 2021, 15, 2423-2438.	4.6	10
493	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 621-631.	2.0	35
494	Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer. <i>Pathology Research and Practice</i> , 2021, 221, 153412.	2.3	4
495	Comments on â€“High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsâ€™. <i>European Journal of Cancer</i> , 2021, 153, 265-266.	2.8	0
496	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). <i>Cancers</i> , 2021, 13, 2594.	3.7	2



#	ARTICLE	IF	CITATIONS
497	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 672219.	4.8	2
498	The relationship between TEM8 and early diagnosis and prognosis of lung cancer. <i>Minerva Medica</i> , 2021, 112, 359-364.	0.9	7
499	The prognostic value of weight and body composition changes in patients with non-small cell lung cancer treated with nivolumab. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 657-664.	7.3	18
500	Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2707.	3.7	8
501	An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	1.0	4
502	KRAS G12C Mutations in NSCLC: From Target to Resistance. <i>Cancers</i> , 2021, 13, 2541.	3.7	39
503	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021, 21, 549.	2.6	10
504	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021, 17, 1709-1719.	2.4	10
505	Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. <i>Lung Cancer</i> , 2021, 155, 163-169.	2.0	23
506	Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 437-444.	3.1	10
507	Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100147.	1.1	3
508	Adverse overall survival impact of PD-L1 positivity in patients with KRAS G12C mutation is abolished by the immunotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e856-e858.	2.6	1
509	Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 809-817.	2.4	2
510	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , 2021, 13, 2638.	3.7	32
511	Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in MAori and Pacifica in New Zealand. <i>PLoS ONE</i> , 2021, 16, e0251357.	2.5	6
512	Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1581-1590.	1.2	4
513	Encapsulation of a CpG oligonucleotide in cationic liposomes enhances its local antitumor activity following pulmonary delivery in a murine model of metastatic lung cancer. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120504.	5.2	19
514	Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3643-3655.	6.4	53



#	ARTICLE	IF	CITATIONS
515	Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , .		0
516	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer, 2021, 21, 743.	2.6	3
517	Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone. Frontiers in Public Health, 2021, 9, 677862.	2.7	6
518	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers, 2021, 13, 2935.	3.7	13
519	Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay. Annals of Translational Medicine, 2021, 9, 922-922.	1.7	8
520	Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients. Surgical Oncology, 2021, 37, 101611.	1.6	2
521	Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. Translational Lung Cancer Research, 2021, 10, 2588-2602.	2.8	5
522	Factors associated with early lung cancer mortality: a systematic review. Expert Review of Anticancer Therapy, 2021, 21, 1125-1133.	2.4	8
523	STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway. Neoplasia, 2021, 23, 607-623.	5.3	12
524	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	1.1	5
525	Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer, 2021, 21, 689.	2.6	2
526	Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. Annals of Translational Medicine, 2021, 9, 937-937.	1.7	9
527	Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. Journal of Molecular Pathology, 2021, 2, 197-206.	1.2	2
528	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 703893.	2.8	33
529	Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer. Journal of Clinical Medicine, 2021, 10, 2889.	2.4	49
530	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The "LUNGFI" Study. Cancers, 2021, 13, 3172.	3.7	6
531	Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review. Cancers, 2021, 13, 3144.	3.7	5
532	Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open, 2021, 6, 100113.	4.5	17

#	ARTICLE	IF	CITATIONS
533	Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer. <i>Cancer Reports</i> , 2021, , e1487.	1.4	2
534	Drugging the Undruggable: Advances on RAS Targeting in Cancer. <i>Genes</i> , 2021, 12, 899.	2.4	44
535	Immunotherapy in malignant pleural mesothelioma: a review of literature data. <i>Translational Lung Cancer Research</i> , 2021, 10, 2988-3000.	2.8	11
536	Lin28A promotes the proliferation and stemness of lung cancer cells via the activation of mitogen-activated protein kinase pathway dependent on microRNA let-7c. <i>Annals of Translational Medicine</i> , 2021, 9, 982-982.	1.7	3
537	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2917-2936.	2.8	18
538	Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non-small cell lung cancer cells. <i>Oncology Reports</i> , 2021, 46, .	2.6	5
539	Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2198-2204.	1.9	19
540	New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature. <i>Annals of Translational Medicine</i> , 2021, 9, 959-959.	1.7	6
541	N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 657087.	3.5	19
542	High Tumor Burden in Metastatic Non-Small Cell Lung Cancer: Defining the Concept. <i>Cancer Management and Research</i> , 2021, Volume 13, 4665-4670.	1.9	5
543	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021, 150, 203-210.	2.8	5
544	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	2.8	21
545	Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 616380.	2.6	7
546	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. <i>Lung Cancer</i> , 2021, 156, 91-99.	2.0	11
547	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3020.	3.7	11
548	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	4.2	22
549	Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2715-2732.	2.8	11
550	False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small cell lung cancer patients. <i>Histopathology</i> , 2021, 79, 480-490.	2.9	6

#	ARTICLE	IF	CITATIONS
551	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3486-3502.	2.8	8
552	Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1075-1085.	1.1	19
553	lncRNA OXCT1-AS1 Promotes Metastasis in Non-Small-Cell Lung Cancer by Stabilizing LEF1, In Vitro and In Vivo. <i>BioMed Research International</i> , 2021, 2021, 1-15.	1.9	8
554	The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectivesâ€”State of the Art. <i>Cancers</i> , 2021, 13, 3711.	3.7	27
555	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 671127.	2.8	2
556	An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2021, 21, 802.	2.6	5
557	Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for <i>EGFR</i>-mutated resectable non-small-cell lung cancer: NeoADAURA. <i>Future Oncology</i> , 2021, 17, 4045-4055.	2.4	76
558	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.	2.4	6
559	Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 673901.	2.8	8
560	Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategiesâ€”a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3457-3472.	2.8	1
561	lncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape. <i>Frontiers in Genetics</i> , 2021, 12, 674856.	2.3	15
562	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1909-1924.	1.1	212
563	Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA. <i>Clinical Lung Cancer</i> , 2021, 22, 292-300.e1.	2.6	4
564	Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Nonâ€”Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. <i>World Neurosurgery</i> , 2021, 151, e324-e331.	1.3	9
565	Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. <i>Cells</i> , 2021, 10, 1912.	4.1	13
566	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200294.	7.1	7
567	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIb Studies. <i>Frontiers in Oncology</i> , 2021, 11, 709877.	2.8	6
568	Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	0

#	ARTICLE	IF	CITATIONS
569	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	2.4	7
570	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	2.0	7
571	Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1112-1121.	3.0	10
572	Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan. <i>Frontiers in Pharmacology</i> , 2021, 12, 697711.	3.5	0
573	The treatment of advanced lung adenocarcinoma with activating EGFR mutations. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2475-2482.	1.8	5
574	Local for advanced, is this a paradox?. <i>Translational Lung Cancer Research</i> , 2021, 10, 3324-3328.	2.8	0
575	Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Nonâ€“Small Cell Lung Cancer: Results From a Phase 1b Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 273-281.	2.6	6
576	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. <i>Cancers</i> , 2021, 13, 3376.	3.7	8
577	Current and future research efforts in oligometastatic non-small cell lung cancerâ€“a systematic review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3473-3485.	2.8	3
578	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 676732.	2.8	14
579	A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses. <i>Cancers</i> , 2021, 13, 3641.	3.7	11
580	Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions. <i>Diagnostics</i> , 2021, 11, 1319.	2.6	3
581	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	2.5	22
582	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2040-2050.	1.1	26
583	A clinical variableâ€“based nomogram could predict the survival for advanced NSCLC patients receiving secondâ€“line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	2.8	2
584	Brigatinib as a treatment of ALK-positive non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 299-305.	0.7	0
585	Toxicity of pemetrexed during renal impairment explainedâ€“Implications for safe treatment. <i>International Journal of Cancer</i> , 2021, 149, 1576-1584.	5.1	9
586	Haemodialysed patient with lung cancer in the COVID-19 era: a clinical challenge. <i>BMJ Case Reports</i> , 2021, 14, e243462.	0.5	1

#	ARTICLE	IF	CITATIONS
587	The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3409-3419.	2.8	13
588	Lobectomy Can Improve the Survival of Patients With Non-small Cell Lung Cancer With Lung Oligometastatic. <i>Frontiers in Surgery</i> , 2021, 8, 685186.	1.4	3
589	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	7.1	11
590	DASC-21: a novel geriatric assessment for discriminating best supportive care in older patients with inoperable advanced non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1628-1635.	1.3	0
592	Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 1483-1491.	3.2	7
593	EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?. <i>Cancer Medicine</i> , 2021, 10, 6167-6188.	2.8	8
594	Improvement of Pulmonary Photodynamic Therapy: Nebulisation of Curcumin-Loaded Tetraether Liposomes. <i>Pharmaceutics</i> , 2021, 13, 1243.	4.5	16
595	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. <i>Diagnostics</i> , 2021, 11, 1452.	2.6	5
596	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center. <i>Oncologist</i> , 2021, 26, e2143-e2150.	3.7	12
597	KRAS Targeting and Resistance: Anticipating the Expectable. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1239-1241.	1.1	1
598	Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase. <i>Molecular and Clinical Oncology</i> , 2021, 15, 211.	1.0	6
599	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 93-102.	2.7	1
600	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	2.8	21
601	Pathogenesis and therapeutic strategy in platinum resistance lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188577.	7.4	29
602	Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6389-6401.	1.9	10
603	Hyperhydration with cisplatin does not influence pemetrexed exposure. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 871-876.	2.4	2
604	Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 719-726.	4.2	33
605	Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation. <i>Meditsinskiy Sovet</i> , 2021, , 42-47.	0.5	0

#	ARTICLE	IF	CITATIONS
606	Incidence and Prevalence Analysis of Non-Small-Cell and Small-Cell Lung Cancer Using Administrative Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9076.	2.6	5
607	Current and Future Development in Lung Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8661.	4.1	233
609	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021, 17, e1085-e1093.	2.9	8
610	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2022, 17, 103-115.	1.1	89
611	Genomic profile as a possible diagnostic and prognostic marker in upper tract urothelial carcinoma. <i>BJU International</i> , 2022, 130, 92-101.	2.5	5
612	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	3.4	5
613	Cost-effectiveness analysis of a lung cancer screening programme in Spain. <i>European Journal of Cancer Prevention</i> , 2022, 31, 235-244.	1.3	5
614	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 987-996.	0.7	1
615	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression $\geq 50\%$ . <i>Future Oncology</i> , 2021, 17, 3007-3016.	2.4	6
616	EGFR plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs : A meta-analysis. <i>Cancer Reports</i> , 2021, , e1544.	1.4	2
617	Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing Weighting. <i>Frontiers in Medicine</i> , 2021, 8, 689114.	2.6	6
618	Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 447-450.	2.0	3
619	EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors. <i>Cancer Genetics</i> , 2021, 256-257, 131-135.	0.4	8
620	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer: A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , 2021, 28, 3268-3279.	2.2	12
621	A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient. <i>Medicine (United States)</i> , 2021, 100, e26801.	1.0	0
622	A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients. <i>Lung</i> , 2021, 199, 395-402.	3.3	2
623	A potentially valuable nano graphene oxide/USPIO tumor diagnosis and treatment system. <i>Materials Science and Engineering C</i> , 2021, 128, 112293.	7.3	9
625	Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition. <i>Oncotarget</i> , 2021, 12, 1946-1952.	1.8	3



#	ARTICLE	IF	CITATIONS
626	The smell of lung disease: a review of the current status of electronic nose technology. Respiratory Research, 2021, 22, 246.	3.6	34
627	Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy. Translational Lung Cancer Research, 2021, 10, 3782-3792.	2.8	11
628	Transient asymptomatic pulmonary opacities and interstitial lung disease in <i>EGFR</i> -mutated non-small cell lung cancer treated with osimertinib. Tumori, 2022, 108, 592-599.	1.1	5
629	Postoperative long-term survival of non-small cell lung cancer patients with skip-N2 metastases. Surgical Oncology, 2021, 38, 101505.	1.6	3
630	Treatment of brain metastases in ALK-positive non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2021, 165, 103400.	4.4	10
631	Natural killer cell-based immunotherapy for lung cancer: Challenges and perspectives (Review). Oncology Reports, 2021, 46, .	2.6	14
632	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. Journal of Personalized Medicine, 2021, 11, 971.	2.5	5
634	Evaluation of Cytologic Sample Preparations for Compatibility With Nucleic Acid Analysis. American Journal of Clinical Pathology, 2022, 157, 293-304.	0.7	6
635	Classifying Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 4822.	3.7	8
636	Intracranial effect of osimertinib in relapsed <i>EGFR</i> -mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta Oncologica, 2021, 60, 1565-1571.	1.8	2
637	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 241-251.	27.0	393
638	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers, 2021, 13, 4543.	3.7	14
639	Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems. Advances in Medical Sciences, 2021, 66, 336-342.	2.1	4
640	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2021, 2, 100206.	1.1	3
641	Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. Journal of Controlled Release, 2021, 337, 27-58.	9.9	44
642	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. Biomedicines, 2021, 9, 1299.	3.2	10
643	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. Case Reports in Oncology, 2022, 14, 1323-1327.	0.7	4
644	Targeted therapies for unresectable stage III non-small cell lung cancer. Mediastinum, 2021, 5, 22-22.	1.1	7



#	ARTICLE	IF	CITATIONS
645	Effectiveness and Safety of Transthoracic Ultrasound in Guiding Percutaneous Needle Biopsy in the Lung and Comparison vs. CT Scan in Assessing Morphology of Subpleural Consolidations. <i>Diagnostics</i> , 2021, 11, 1641.	2.6	6
646	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021, 162, 42-53.	2.0	22
647	Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2021, 159, 117-126.	2.0	4
648	Real-world insights into patients with advanced NSCLC and MET alterations. <i>Lung Cancer</i> , 2021, 159, 96-106.	2.0	11
649	Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative. <i>BMJ Open</i> , 2021, 11, e046396.	1.9	8
650	Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC. <i>Targeted Oncology</i> , 2021, 16, 687-695.	3.6	14
651	Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4671-4692.	2.0	6
652	A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. <i>Lung Cancer</i> , 2021, 159, 1-9.	2.0	28
653	Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. <i>Pharmacoeconomics - Open</i> , 2022, 6, 241-252.	1.8	3
654	Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small cell lung cancer treated with pembrolizumab. <i>Molecular Oncology</i> , 2021, 15, 2923-2940.	4.6	17
655	Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104685.	2.1	3
656	Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2527-2538.	4.1	6
657	A meta-analysis of front-line therapy of osimertinib in treating non-small cell lung cancer. <i>Food Science and Technology</i> , 0, , .	1.7	1
658	Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. <i>Biology</i> , 2021, 10, 890.	2.8	4
659	Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. <i>Radiation Oncology</i> , 2021, 16, 184.	2.7	2
660	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , 2021, 398, 1344-1357.	13.7	689
661	Lung Cancer in Belgium. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1610-1621.	1.1	4
662	Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103454.	4.4	15

#	ARTICLE	IF	CITATIONS
663	Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study. <i>Lipids in Health and Disease</i> , 2021, 20, 69.	3.0	13
664	eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 36-43.	2.0	11
665	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. <i>Lung Cancer</i> , 2021, 160, 118-126.	2.0	5
666	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	4.1	10
667	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 44-49.	2.0	1
668	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. <i>ESMO Open</i> , 2021, 6, 100253.	4.5	17
669	The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 713530.	2.8	54
670	A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion. <i>Lung Cancer</i> , 2021, 161, 114-121.	2.0	8
671	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02â€15 study). <i>Lung Cancer</i> , 2021, 161, 122-127.	2.0	2
672	Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2021, 161, 98-107.	2.0	1
673	Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113568.	10.1	10
674	Molecular Targetable Pathwaysâ€ALK. , 2022, , 853-864.		0
675	Management of Advanced Disease in NSCLC. , 2022, , 912-920.		0
676	Overview of Lung Cancer. , 2022, , 621-633.		0
677	Management of Locally Advanced Non-Small Cell Lung Cancer. , 2022, , 810-824.		1
678	Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type. <i>Translational Cancer Research</i> , 2021, 10, 184-194.	1.0	0
679	Immunotherapy in non-small cell lung cancer: update and new insights. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	23
680	Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	3.2	10

#	ARTICLE	IF	CITATIONS
681	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	3.2	1
682	Image-Guided Brachytherapy in Oligometastasis: Criteria for Patient Selection from an Oncological Perspective. , 2021, , 75-89.		0
683	EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer, 2021, 21, 5.	2.6	15
684	Epidermal growth factor receptor (EGFR)â€™tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2022, 34, 416-423.	1.1	9
685	Brigatinib in <i>ALK</i>-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncology, 2021, 17, 169-181.	2.4	5
686	ALK rearranged lung cancer: TKI treatment and outcome. , 2021, , 31-53.		0
687	Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinomaâ€™a case report and a literature review. Porto Biomedical Journal, 2021, 6, e124.	1.0	2
689	Tumor mutational burden on cytological samples: A pilot study. Cancer Cytopathology, 2021, 129, 460-467.	2.4	34
690	Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology, 2020, 152, 102980.	4.4	12
691	Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. JTO Clinical and Research Reports, 2020, 1, 100077.	1.1	18
692	Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide. Medicine (United States), 2020, 99, e23592.	1.0	2
693	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	4.5	4
694	Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. JCI Insight, 2020, 5, .	5.0	16
695	Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer. Journal of Oncology Pharmacy Practice, 2021, 27, 1528-1533.	0.9	6
696	Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells. Development & Reproduction, 2020, 24, 113-123.	0.4	14
697	Overexpression and Selective Anticancer Efficacy of in Mutant Lung Cancers. Molecules and Cells, 2019, 42, 804-809.	2.6	23
698	Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1341-1348.	2.3	7
699	PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread. Endocrine Connections, 2019, 8, 1168-1175.	1.9	19

#	ARTICLE	IF	CITATIONS
700	Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype. <i>Endocrine Connections</i> , 2019, 8, 1600-1606.	1.9	6
701	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1478-1478.	1.7	17
702	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 351-351.	1.7	14
703	Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial. <i>Translational Cancer Research</i> , 2019, 8, S145-S148.	1.0	1
704	How selecting best upfront therapy for metastatic disease?â€”Focus on ROS1-rearranged disease. <i>Translational Lung Cancer Research</i> , 2020, 9, 2686-2695.	2.8	6
705	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	2.8	16
706	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. <i>Translational Lung Cancer Research</i> , 2019, 8, S435-S438.	2.8	2
707	<p>Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 113-121.	2.7	7
708	<p>Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9305-9321.	2.0	16
711	The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2019, 116, 849-856.	0.9	6
712	Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 532292.	2.8	6
713	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	3.7	5
714	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. <i>Cancers</i> , 2021, 13, 6.	3.7	30
715	Role of liquid biopsy for thoracic cancers immunotherapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 183-199.	0.8	5
716	Plasma platinâ€³: A tumor marker in patients with nonâ€³smallâ€³cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2020, 21, 1-1.	1.8	4
717	Endobronchial ultrasound-guided transbronchial needle aspiration can improve the diagnostic accuracy of positron emission tomography/computed tomography in hilar and/or mediastinal lymphadenopathy. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 1490.	0.9	5
718	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020, 52, 284-291.	3.0	4
719	Biomarker Testing Rates in Patients with Advanced Non-Small Cell Lung Cancer Treated in the Community. <i>Journal of Cancer Therapy</i> , 2019, 10, 971-984.	0.4	9

#	ARTICLE	IF	CITATIONS
720	Diagnostic usefulness of bronchoscopy for peripheral pulmonary lesions in patients with idiopathic pulmonary fibrosis. <i>Journal of Thoracic Disease</i> , 2021, 13, 0-0.	1.4	0
721	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib. <i>Open Medicine (Poland)</i> , 2021, 16, 1602-1607.	1.3	1
722	Essais contrôlés randomisés : quelques clés méthodologiques pour comprendre. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S55-2S62.	0.0	0
727	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
728	In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. <i>International Journal of Cancer</i> , 2021, , .	5.1	6
729	Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group. <i>Clinical and Translational Oncology</i> , 2022, 24, 446-459.	2.4	9
730	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4583.	2.4	3
731	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	2.0	2
732	Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding. <i>Annals of Oncology</i> , 2021, 32, 1463-1465.	1.2	0
733	Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review. <i>Thoracic Cancer</i> , 2021, 12, 3062-3067.	1.9	12
734	Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. <i>Frontiers in Oncology</i> , 2021, 11, 692788.	2.8	16
735	The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 157-167.	1.5	1
736	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	1.1	114
737	Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15379-15401.	6.4	8
738	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	4.5	91
740	Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 21-30.	2.3	7
741	A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. <i>Targeted Oncology</i> , 2021, 16, 801-811.	3.6	13
742	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. <i>Clinical Lung Cancer</i> , 2022, 23, e69-e82.	2.6	31

#	ARTICLE	IF	CITATIONS
743	A word of caution on using tumor biomarker reference change values to guide medical decisions and the need for alternatives. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 553-555.	2.3	12
744	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 5299.	3.7	2
745	Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. <i>Lung Cancer</i> , 2022, 166, 270-278.	2.0	21
746	First-line nab paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. <i>Cancer Medicine</i> , 2021, 10, 8127-8137.	2.8	1
747	Small cell transformation in crizotinib-resistant ROS1 rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report. <i>Thoracic Cancer</i> , 2021, 12, 3068-3071.	1.9	5
748	Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors. <i>BMC Cancer</i> , 2021, 21, 1089.	2.6	3
749	The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. <i>Lung Cancer</i> , 2021, 162, 36-41.	2.0	5
750	Commentary on Mascaux et al., Immune Evasion before Tumour Invasion in Early Lung Squamous Carcinogenesis. <i>Nature</i> . 2019;571:570-5. <i>Med One</i> , 0, , .	1.0	0
751	Chemotherapy and molecular biological therapy. , 2019, , 463-471.		0
752	The role of developmental signaling pathways in non-small cell lung carcinoma. <i>Journal of Molecular and Clinical Medicine</i> , 2019, 2, 41.	0.2	1
753	Expanding the knowledge of oligometastatic disease—but uncertainties remain significant. <i>Journal of Thoracic Disease</i> , 2019, 11, S2008-S2011.	1.4	0
754	Extracranial Abscopal Effects Induced by Brain Radiation in Advanced Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 951-957.	1.3	5
755	When not even four ALK inhibitors are enough. <i>Onkologie (Czech Republic)</i> , 2020, 14, 40-43.	0.1	0
756	Lung cancer and chronic obstructive pulmonary disease association: epidemiology, diagnostic and treatment aspects. <i>Pneumologia</i> , 2020, 69, 22-28.	0.1	0
759	Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	27
760	Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?. <i>European Respiratory Journal</i> , 2021, 58, 2101637.	6.7	2
761	Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. <i>Journal of Personalized Medicine</i> , 2021, 11, 1102.	2.5	40
762	Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). <i>Cancer</i> , 2022, 128, 778-787.	4.1	23



#	ARTICLE	IF	CITATIONS
763	Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8241-8255.	1.9	11
764	Cancers bronchiques. , 2020, , 139-146.e2.		0
765	Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?. Translational Lung Cancer Research, 2020, 9, 2518-2520.	2.8	0
766	Cutaneous Metastasis as the First Presentation of Non-Small-Cell Lung Cancer with a BRAF Mutation: A Case Report. OncoTargets and Therapy, 2020, Volume 13, 13143-13149.	2.0	5
767	PET Beyond Pictures. , 2021, , 131-150.		0
768	Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer. Current Oncology, 2021, 28, 60-68.	2.2	8
769	The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer. Expert Opinion on Biological Therapy, 2021, 21, 303-309.	3.1	3
770	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. Translational Lung Cancer Research, 2020, 9, 2599-2617.	2.8	10
771	Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy. Meditsinskiy Sovet, 2020, , 194-198.	0.5	0
772	A Rare Case of Synchronous Waldenström's Macroglobulinemia and Cutaneous Squamous Cell Carcinoma with a Lung Mass: A Diagnostic and Management Dilemma. Case Reports in Oncology, 2021, 13, 1474-1482.	0.7	0
773	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
774	Contribution of the Idylla™ System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations. Current Oncology, 2021, 28, 4432-4445.	2.2	12
775	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2022, 17, 423-433.	1.1	89
776	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. Drug Safety, 2021, 44, 1271-1281.	3.2	10
777	Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037812.	6.2	8
778	Highly sensitive quantification of pemetrexed in human plasma by means of UPLC-MS/MS to support microdosing studies. Biomedical Chromatography, 2021, , e5277.	1.7	4
779	First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis. Cancer Medicine, 2021, 10, 9139.	2.8	4
780	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. Cancer Journal (Sudbury, Mass ), 2020, 26, 525-536.	2.0	12

#	ARTICLE	IF	CITATIONS
781	Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. <i>Clinical Medicine</i> , 2020, 20, 551-559.	1.9	7
782	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. <i>Respiratory Medicine and Research</i> , 2021, 80, 100795.	0.6	5
784	Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma. <i>EXCLI Journal</i> , 2020, 19, 230-238.	0.7	3
786	Combination of Brachytherapy with Iodine-125 Seeds and Systemic Chemotherapy versus Systemic Chemotherapy Alone for Synchronous Extracranial Oligometastatic Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2020, 12, 8209-8220.	1.9	1
787	EGFR and non-small cell lung cancer: implications for surgical practice. <i>Annals of Translational Medicine</i> , 2020, 8, 1115.	1.7	0
788	Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. <i>Translational Lung Cancer Research</i> , 2020, 9, 2194-2198.	2.8	1
789	Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype. <i>Current Health Sciences Journal</i> , 2020, 46, 300-304.	0.2	0
791	Immunotherapy in non-small cell lung cancer: Update and new insights. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 1-21.	0.3	16
792	Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-14020 and reference bevacizumab in stage IV non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	3.2	6
793	Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 574-582.	2.2	5
794	Recent advances in lung cancer genomics: Application in targeted therapy. <i>Advances in Genetics</i> , 2021, 108, 201-275.	1.8	5
795	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103538.	4.4	13
796	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 15, 101279.	3.7	7
797	Lungenkarzinom. , 2022, , 242-246.		0
798	Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies. <i>Frontiers in Medicine</i> , 2021, 8, 761078.	2.6	1
799	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	1.1	429
800	PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. <i>Lung Cancer Management</i> , 2021, 10, LMT53.	1.5	1
801	Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103564.	4.4	12

#	ARTICLE	IF	CITATIONS
802	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 983-999.	2.3	2
803	Kinase Inhibitorsâ€™ Effects on Innate Immunity in Solid Cancers. Cancers, 2021, 13, 5695.	3.7	5
804	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
805	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.3	5
806	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer, 2021, 21, 1247.	2.6	3
807	A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Annals of Oncology, 2022, 33, 181-192.	1.2	51
808	Baseline tumour size is an independent prognostic factor for overall survival in PD-L1â€™50% non-small cell lung cancer patients treated with first-line pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 1747-1756.	4.2	5
809	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2985-2994.	2.5	1
810	Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations. International Journal of Molecular Sciences, 2021, 22, 12867.	4.1	13
811	Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable nonâ€™small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2021, , .	1.1	4
812	Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed. Applied Sciences (Switzerland), 2021, 11, 11334.	2.5	0
813	Realâ€™world evaluation of molecular testing and treatment patterns for EGFR mutations in nonâ€™small cell lung cancer in Latin America. Molecular and Clinical Oncology, 2021, 16, 6.	1.0	4
814	STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact. Cells, 2021, 10, 3129.	4.1	30
815	Brain metastases: the role of clinical imaging. British Journal of Radiology, 2022, 95, 20210944.	2.2	18
816	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology, 2021, 28, 4552-4576.	2.2	4
817	Extracellular Vesicles in Lung Cancer Metastasis and Their Clinical Applications. Cancers, 2021, 13, 5633.	3.7	14
818	Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. Journal of Modern Oncology, 2021, 23, 408-417.	0.3	0
819	Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy. BMC Cancer, 2021, 21, 1252.	2.6	2

#	ARTICLE	IF	CITATIONS
821	Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community. Journal of Thoracic Oncology, 2021, 16, 1976-1978.	1.1	1
822	Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Scientific Reports, 2021, 11, 23274.	3.3	13
823	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points. Cancers, 2021, 13, 6063.	3.7	8
824	Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open, 2021, 6, 100319.	4.5	47
825	Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	3.2	6
826	A scRNA-seq Based Prediction Model of EGFR-TKIs Resistance in Patients With Non-Small Cell Lung Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
827	Impact of epidermal growth factor receptor T790M testing in relapsed non-small cell lung cancer: A narrative review of the T790M reflex testing algorithm. Cancer Research Statistics and Treatment, 2021, 4, 692.	0.6	3
828	Tumors: Non-small Cell Lung Cancer. , 2021, , 5270-5279.		0
829	Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 56.	0.2	0
830	Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study. Clinical Oncology, 2022, 34, 459-468.	1.4	11
831	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 688679.	2.8	13
832	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	7.0	14
833	EGFR and non-small cell lung cancer: implications for surgical practice. Annals of Translational Medicine, 2020, 8, 1115-1115.	1.7	0
834	Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. Translational Lung Cancer Research, 2020, 9, 2194-2198.	2.8	4
835	Immunotherapy using PD-1/PDL-1 inhibitors in triple-negative breast cancer: a systematic review. Oncology Reviews, 2021, 15, 497.	1.8	8
836	ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Current Oncology, 2022, 29, 641-658.	2.2	34
837	Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers, 2022, 14, 718.	3.7	5
838	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. The Cochrane Library, 2022, 2022, CD013453.	2.8	18

#	ARTICLE	IF	CITATIONS
840	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1640-1650.	7.0	19
841	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	7.0	19
842	Pre-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 1574-1583.	4.1	14
843	SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway. <i>Journal of Cancer</i> , 2022, 13, 527-540.	2.5	7
844	Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. <i>Lung Cancer</i> , 2022, 163, 96-106.	2.0	35
845	Lung Cancer and Self-Management Interventions: A Systematic Review of Randomised Controlled Trials. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 536.	2.6	8
846	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. <i>Frontiers in Oncology</i> , 2022, 12, 766066.	2.8	3
847	Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation. <i>Frontiers in Medicine</i> , 2021, 8, 772998.	2.6	3
848	The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1103-1110.	4.7	2
849	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	1.6	242
850	Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 746707.	3.5	9
851	Biomarkers in Pulmonary Carcinomas. , 2022, , 99-128.		2
852	Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 786089.	2.8	2
853	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	1.9	6
854	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	3.6	6
855	Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. <i>Oncologist</i> , 2022, 27, 7-12.	3.7	3
856	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	3.0	29
857	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21

#	ARTICLE	IF	CITATIONS
858	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 2022, 7, 100333.	4.5	16
859	Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer. Lung Cancer, 2022, 166, 1-8.	2.0	10
860	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung Cancer, 2022, 165, 34-42.	2.0	20
861	Monitoring tumor growth rate to predict immune checkpoint inhibitorsâ€™ treatment outcome in advanced NSCLC. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110583.	3.2	2
862	Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	4.0	8
863	Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples. Scottish Medical Journal, 2022, 67, 18-27.	1.3	2
864	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs, 2022, 36, 137-151.	4.6	6
865	Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations. Cancers, 2022, 14, 832.	3.7	7
866	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with EGFR <sup>m+</sup> non-small-cell lung cancer. Future Oncology, 2022, 18, 1485-1497.	2.4	0
867	Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. Cancers, 2022, 14, 851.	3.7	5
868	Management of oligoprogression in non-small cell lung cancer patients. Medical Oncology, 2022, 39, 56.	2.5	1
869	Machine Learningâ€“Based Analysis of Treatment Sequences Typology in Advanced Nonâ€“Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clinical Cancer Informatics, 2022, 6, e2100108.	2.1	4
870	Cost-Sensitive Uncertainty Hypergraph Learning for Identification of Lymph Node Involvement With CT Imaging. Frontiers in Medicine, 2022, 9, 840319.	2.6	1
871	Targeting KRAS in NSCLC: Old Failures and New Options for â€œNon-G12câ€–Patients. Cancers, 2021, 13, 6332.	3.7	10
872	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. Frontiers in Oncology, 2021, 11, 792385.	2.8	1
874	Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review. Anticancer Research, 2022, 42, 373-379.	1.1	4
875	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers, 2021, 13, 6259.	3.7	17
876	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. Expert Review of Precision Medicine and Drug Development, 2022, 7, 29-38.	0.7	0



#	ARTICLE	IF	CITATIONS
877	OUP accepted manuscript. Oncologist, 2022, , .	3.7	3
878	A narrative review of ERBB2 in non-small cell lung carcinoma. Cancer Research Statistics and Treatment, 2022, 5, 97.	0.6	1
879	Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2022, , .	1.3	0
880	Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers, 2022, 14, 1184.	3.7	16
881	Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series. Case Reports in Oncology, 2022, 15, 138-148.	0.7	2
882	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Annals of Oncology, 2022, 33, 511-521.	1.2	36
884	Model Calibration of Pharmacokinetic-Pharmacodynamic Lung Tumour Dynamics for Anticancer Therapies. Journal of Clinical Medicine, 2022, 11, 1006.	2.4	8
885	Clinical impact of cerebral infarction in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2022, 27, 863-870.	2.2	2
886	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer, 2022, 21, 61.	19.2	6
887	Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell International, 2022, 22, 82.	4.1	8
888	BSREM for Brain Metastasis Detection with 18F-FDG-PET/CT in Lung Cancer Patients. Journal of Digital Imaging, 2022, 35, 581-593.	2.9	5
889	Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2022, 114, 635-644.	0.8	18
890	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 896.	3.7	36
891	Evolving concepts in COPD and lung cancer: a narrative review. Minerva Medica, 2022, 113, .	0.9	11
893	Encorafenib plus binimetinib in patients with <i>BRAF</i> <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9
894	Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner. Cancers, 2022, 14, 1628.	3.7	9
895	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
896	Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring <i>EGFR</i> Mutations. Anticancer Research, 2022, 42, 2145-2157.	1.1	10

#	ARTICLE	IF	CITATIONS
897	Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer. Turkish Journal of Internal Medicine, 0, , .	0.6	2
898	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. Cancers, 2022, 14, 1682.	3.7	2
899	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC Cancer, 2022, 22, 255.	2.6	11
900	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. British Journal of Cancer, 2022, 127, 383-393.	6.4	36
901	Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Cancers, 2022, 14, 1321.	3.7	29
902	Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges. Journal of Personalized Medicine, 2022, 12, 480.	2.5	19
903	A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. Npj Precision Oncology, 2022, 6, 19.	5.4	20
904	Clinical and economic impact of â€œROS1-testingâ€™ strategy compared to a â€œno-ROS1-testingâ€™ strategy in advanced NSCLC in Spain. BMC Cancer, 2022, 22, 292.	2.6	2
905	Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. The Cochrane Library, 2022, 2022, .	2.8	0
906	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i> + Nonâ€œsmall Cell Lung Cancer in the Global Phase III ALEX Trial. Clinical Cancer Research, 2022, 28, 1800-1808.	7.0	26
907	ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer. Oncology and Therapy, 2022, 10, 13-22.	2.6	2
908	Single agent VS-6766 or VS-6766 plus defactinib in<i>KRAS</i>-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncology, 2022, 18, 1907-1915.	2.4	11
909	Generalizability of ORIENT-11 trial results to a USÂstandard of care cohort with advanced non-small-cell lung cancer. Future Oncology, 2022, , .	2.4	2
910	Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2022, 12, 837630.	2.8	0
912	Aumolertinib: A Review in Non-Small Cell Lung Cancer. Drugs, 2022, 82, 577-584.	10.9	9
913	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	2.2	5
914	Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasisâ€œA Case Series of Three Patients. Current Oncology, 2022, 29, 2225-2239.	2.2	2
915	European Respiratory Society International Congress 2021: highlights from best-abstract awardees. Breathe, 2022, 18, 210176.	1.3	1

#	ARTICLE	IF	CITATIONS
916	Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study. <i>Cancers</i> , 2022, 14, 1344.	3.7	3
917	Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3631.	4.1	10
918	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in Peopleâ€™s Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	1.1	15
919	Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. <i>Cancers</i> , 2022, 14, 1465.	3.7	0
920	Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?. <i>Anticancer Research</i> , 2022, 42, 1987-1995.	1.1	2
921	Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. <i>ESMO Open</i> , 2022, 7, 100418.	4.5	6
922	Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 840889.	3.5	0
923	Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. <i>Lung Cancer</i> , 2022, 167, 87-97.	2.0	11
924	Lung Cancer in Sudan. <i>Journal of Thoracic Oncology</i> , 2022, 17, 489-498.	1.1	1
925	Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1211-1220.	2.5	4
926	Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-world Standard of Care in Patients With BRAF-Mutated Advanced Nonâ€™Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100324.	1.1	0
927	Circular RNA circ_0002360 regulates the Taxol resistance and malignant behaviors of Taxol-resistant non-small cell lung cancer cells by microRNA-585-3p-dependent modulation of G protein regulated inducer of neurite outgrowth 1. <i>Bioengineered</i> , 2022, 13, 9070-9085.	3.2	6
928	Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report. <i>Lung Cancer</i> , 2022, 166, 132-134.	2.0	3
929	Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages. <i>Cancers</i> , 2022, 14, 1893.	3.7	1
930	Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial. <i>BMJ Open</i> , 2022, 12, e056819.	1.9	6
931	Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2022, 12, 883.	2.6	6
932	Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in nonâ€™small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1449-1456.	1.9	8
933	Lorlatinib for advanced anaplastic lymphoma kinaseâ€™positive nonâ€™small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. <i>European Journal of Cancer</i> , 2022, 166, 51-59.	2.8	14

#	ARTICLE	IF	CITATIONS
934	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer, 2022, 166, 112-125.	2.8	4
935	The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Life Sciences, 2022, 296, 120408.	4.3	6
936	Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla <sup>®</sup> , <sup>®</sup> EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib. European Journal of Cancer, 2022, 166, 38-40.	2.8	6
937	Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib. Medicine (United States), 2021, 100, e27999.	1.0	1
938	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy <sup>®</sup> A Retrospective Bi-Centric Cohort Study. Cancers, 2022, 14, 93.	3.7	7
939	Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report. World Journal of Clinical Cases, 2021, 9, 11419-11424.	0.8	1
940	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell International, 2021, 21, 675.	4.1	9
941	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <i>PD-L1</i> $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	1.9	7
942	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. Cancers, 2021, 13, 6210.	3.7	19
943	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. Cancers, 2021, 13, 6096.	3.7	14
944	Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Oncology Pharmacy Practice, 2023, 29, 138-144.	0.9	1
945	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers, 2022, 14, 92.	3.7	3
946	Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway. Cell Cycle, 2022, 21, 86-100.	2.6	10
947	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small cell lung cancer: A multicenter retrospective trial. Thoracic Cancer, 2022, 13, 228-235.	1.9	7
948	Multicenter real-world data of patients harboring rare mutations other than <i>EGFR</i> or <i>ALK</i> in advanced or metastatic non-small cell lung cancer. Thoracic Cancer, 2022, 13, 380-385.	1.9	2
949	A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring <i>EGFR</i> L747P Mutation With Clinical Response to Multi-targeted Epigenetic and <i>EGFR</i> Inhibition. Anticancer Research, 2022, 42, 441-447.	1.1	2
950	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): Technical Updates and Pathological Yield. Diagnostics, 2021, 11, 2331.	2.6	6
951	Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 6374.	3.7	4

#	ARTICLE	IF	CITATIONS
952	Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With III&IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 735536.	3.5	18
953	CD155 expression and its clinical significance in non&small cell lung cancer. <i>Oncology Letters</i> , 2022, 23, 166.	1.8	7
954	Treatment of Metastatic Brain Lesion Using Osimertinib: A Case Report. I P Pavlov <i>Russian Medical Biological Herald</i> , 2022, 30, 101-107.	0.5	0
956	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	7.7	16
957	Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	1.6	1
958	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. <i>Scientific Reports</i> , 2022, 12, 6367.	3.3	7
959	The Landscape of Immunotherapy Resistance in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 817548.	2.8	27
960	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908.	1.1	23
961	Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4164.	4.1	11
962	Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups. <i>Cancers</i> , 2022, 14, 2019.	3.7	4
963	Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. <i>Acta Oncologica</i> , 2022, 61, 705-713.	1.8	2
964	Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients&A Prospective Cardio-Oncology Study. <i>Cancers</i> , 2022, 14, 2010.	3.7	8
965	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	4.8	15
972	Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences. <i>Cancer Investigation</i> , 2022, 40, 590-603.	1.3	5
974	Prognostic assessment of tumor markers in lung carcinomas. <i>Revista Da Associa&amp;do M&amp;odica Brasileira</i> , 2022, 68, 313-317.	0.7	1
979	Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13108-13116.	0.0	3
980	<i>Pneumologie.</i> , 2022, , 465-540.		0
981	Research Progress on Small Molecules Targeted Therapy in Non-Small Cell Lung Cancer. <i>World Journal of Cancer Research</i> , 2022, 12, 90-98.	0.1	4

#	ARTICLE	IF	CITATIONS
982	Lungenkarzinom. , 2022, , 118-122.		0
983	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precision Oncology, 2022, 6, e2200015.	3.0	8
984	Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer. Cancers, 2022, 14, 2217.	3.7	7
985	Understanding the lived experience of lung cancer: a European social media listening study. BMC Cancer, 2022, 22, 475.	2.6	8
987	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. Vaccines, 2022, 10, 679.	4.4	4
988	Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report. Journal of Modern Oncology, 2022, 24, 41-49.	0.3	0
989	Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence. Journal of Experimental and Clinical Cancer Research, 2022, 41, 163.	8.6	5
990	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. Cancers, 2022, 14, 2352.	3.7	2
992	Effector Memory T Cells and CD45RO+ Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients. Frontiers in Immunology, 2022, 13, 864497.	4.8	3
993	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. Clinical Lung Cancer, 2022, , .	2.6	0
994	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. Journal of Clinical Medicine, 2022, 11, 2629.	2.4	6
995	Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases. Bone Reports, 2022, 16, 101582.	0.4	5
996	Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey. Lung Cancer, 2022, 168, 59-66.	2.0	1
997	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5
998	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). Oncology and Therapy, 2022, , 1.	2.6	0
999	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncology, The, 2022, 23, 781-792.	10.7	150
1000	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3878-3891.	6.4	3
1001	A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer. Acta Oncologica, 2022, 61, 773-776.	1.8	1



#	ARTICLE	IF	CITATIONS
1002	Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics. International Journal of Molecular Sciences, 2022, 23, 5602.	4.1	3
1003	Telerehabilitation physical exercise for patients with lung cancer through the course of their disease: A systematic review. Journal of Telemedicine and Telecare, 2022, , 1357633X2210942.	2.7	2
1004	Prognostic and predictive role of bone metastasis in NSCLC. , 2022, , 49-62.		0
1005	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Nonâ€‘small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clinical Lung Cancer, 2022, 23, e415-e427.	2.6	7
1006	Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. British Journal of Radiology, 2022, 95, .	2.2	1
1007	Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. , 2022, 10, e003890.		37
1008	Added Value of Respiratory Gating in Positron Emission Tomography for the Clinical Management of Lung Cancer Patients. Seminars in Nuclear Medicine, 2022, 52, 745-758.	4.6	6
1009	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 2022, 170, 41-51.	2.0	33
1010	Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients with Treatment-Naïve Advanced ALK-Positive NSCLC. JTO Clinical and Research Reports, 2022, , 100341.	1.1	0
1011	Overcoming immunotherapeutic resistance in PDAC: SIRPÎ±-CD47 blockade. Pharmacological Research, 2022, 181, 106264.	7.1	4
1012	Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis. Translational Oncology, 2022, 22, 101455.	3.7	1
1013	Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research, 2022, 11, 757-775.	2.8	5
1014	Immune checkpoint inhibitors alone vs immune checkpoint inhibitorsâ€‘combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. British Journal of Cancer, 2022, 127, 948-956.	6.4	17
1015	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
1016	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. Cancers, 2022, 14, 2720.	3.7	5
1017	The earlier, the better? A review of neoadjuvant immunotherapy in resectable nonâ€‘smallâ€‘cell lung cancer. Chronic Diseases and Translational Medicine, 2022, 8, 100-111.	1.2	0
1018	Synergism Effect of Dendrobine on Cisplatin in Treatment of H1299 by Modulating the Balance of Treg/Th17. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 105-112.	1.7	1
1020	Local thermal ablative therapies for extracranial oligometastatic disease of nonâ€‘smallâ€‘cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 0, , .	1.1	2

#	ARTICLE	IF	CITATIONS
1021	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer, 2022, 169, 102-114.	2.0	8
1022	Long-Term Survival Following Minimally Invasive Lung Cancer Surgery: Comparing Robotic-Assisted and Video-Assisted Surgery. Cancers, 2022, 14, 2611.	3.7	12
1023	Perioperative targeted therapy for oncogene-driven NSCLC. Lung Cancer, 2022, 172, 160-169.	2.0	15
1024	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A. Journal of Clinical Oncology, 2022, 40, 2295-2307.	1.6	84
1025	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. Drugs - Real World Outcomes, 2022, 9, 333-345.	1.6	4
1026	KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2781.	3.7	12
1028	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression $\geq 50\%$ . Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211050.	3.2	1
1030	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression. JTO Clinical and Research Reports, 2022, 3, 100369.	1.1	3
1031	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Frontiers in Oncology, 0, 12, .	2.8	0
1032	Different Roles of the Insulin-like Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2022, 28, 2052-2064.	1.9	5
1033	First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. Immunotherapy, 2022, 14, 871-877.	2.0	1
1034	Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget, 2022, 13, 812-827.	1.8	2
1035	Whole-genome and transcriptome analysis enhances precision cancer treatment options. Annals of Oncology, 2022, 33, 939-949.	1.2	36
1036	Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2022, 24, 1021-1030.	2.8	13
1037	The occurrence and associated risk factors of brain metastases in well differentiated grade 1 and 2 bronchial neuroendocrine tumours: A single centre retrospective analysis of 280 patients. Journal of Neuroendocrinology, 2022, 34, .	2.6	0
1038	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, .	1.5	4
1039	The clinical utility of <i>cfRNA</i> for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thoracic Cancer, 2022, 13, 2180-2191.	1.9	4
1040	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. Frontiers in Oncology, 0, 12, .	2.8	13

#	ARTICLE	IF	CITATIONS
1041	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4428-4437.	2.2	5
1042	Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). <i>Clinical Cancer Research</i> , 2022, 28, 4222-4231.	7.0	6
1043	Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	5
1044	Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2022, 23, 457-466.	2.6	12
1045	New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 781-796.	4.6	7
1046	BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. <i>Clinical and Translational Oncology</i> , 2023, 25, 10-20.	2.4	9
1047	Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. <i>Micromachines</i> , 2022, 13, 897.	2.9	2
1048	Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	1
1049	Lung nodule diagnosis and cancer histology classification from computed tomography data by convolutional neural networks: A survey. <i>Computers in Biology and Medicine</i> , 2022, 146, 105691.	7.0	27
1050	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 114-123.	2.8	5
1051	Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Dose-Response</i> , 2022, 20, 155932582211116.	1.6	1
1052	Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. <i>Pharmaceuticals</i> , 2022, 15, 796.	3.8	8
1053	Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. <i>Thoracic Cancer</i> , 2022, 13, 2192-2200.	1.9	5
1054	Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China. <i>Cancer Medicine</i> , 0, , .	2.8	2
1055	PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, , .	4.6	3
1056	Immunotherapy in NSCLC Patients with Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7068.	4.1	12
1057	Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. <i>Cancers</i> , 2022, 14, 3275.	3.7	10
1058	Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4811-4826.	2.2	8

#	ARTICLE	IF	CITATIONS
1059	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4981-4997.	2.2	14
1060	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	2.2	2
1061	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	1.2	204
1062	Construction of a Novel MYC-Associated ceRNA Regulatory Network to Identify Prognostic Biomarkers in Colon Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	1.3	1
1063	<sc>Non-small</sc> cell lung cancer with tumor proportion score<math>\geq 90\%Thoracic Cancer, 2022, 13, 2450-2458.	1.9	4
1064	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. <i>Targeted Oncology</i> , 2022, 17, 453-465.	3.6	4
1066	Unplanned pregnancy in an HIV positive woman undergoing alectinib treatment for metastatic non-small-cell lung carcinoma. <i>BMJ Case Reports</i> , 2022, 15, e247530.	0.5	2
1067	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 137-148.	2.3	4
1068	Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. <i>Cancers</i> , 2022, 14, 3452.	3.7	6
1069	Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100527.	4.5	19
1070	Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment – A multicenter analysis. <i>Lung Cancer</i> , 2022, 170, 165-175.	2.0	0
1071	CircRNAs in lung cancer- role and clinical application. <i>Cancer Letters</i> , 2022, 544, 215810.	7.2	9
1072	Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. <i>Radiology and Oncology</i> , 2022, 56, 371-379.	1.7	1
1073	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	27
1074	Multi-lesion radiomics of PET/CT for non-invasive survival stratification and histologic tumor risk profiling in patients with lung adenocarcinoma. <i>European Radiology</i> , 2022, 32, 7056-7067.	4.5	6
1075	A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	2.2	0
1076	Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. , 2022, 10, e004863.		26
1077	Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 109, 102438.	7.7	9

#	ARTICLE	IF	CITATIONS
1078	Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. International Immunopharmacology, 2022, 110, 109030.	3.8	5
1079	Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions. Cancer Epidemiology, 2022, 80, 102232.	1.9	3
1080	Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease. Respiratory Medicine Case Reports, 2022, 39, 101728.	0.4	1
1081	Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care. Current Oncology Reports, 2022, 24, 1607-1618.	4.0	1
1082	Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose-Response, 2022, 20, 155932582211173.	1.6	1
1083	De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report. Medicine (United States), 2022, 101, e29332.	1.0	1
1084	Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precision Oncology, 2022, , .	3.0	0
1085	Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs in Context, 0, 11, 1-17.	2.2	3
1086	Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small Cell Lung Cancer. Value in Health, 2023, 26, 64-70.	0.3	2
1087	Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT). Current Oncology, 2022, 29, 5833-5845.	2.2	2
1088	Response to letter entitled: Re: â€“Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib'. European Journal of Cancer, 2022, 174, 318-320.	2.8	1
1089	Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer. Journal of Computer Assisted Tomography, 2022, 46, 707-715.	0.9	3
1090	Tailoring antiHer2 treatment strategies in breast cancer and beyond. Current Problems in Cancer, 2022, 46, 100892.	2.0	4
1091	Various impacts of driver mutations on the PD-L1 expression of NSCLC. PLoS ONE, 2022, 17, e0273207.	2.5	2
1092	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. International Journal of Molecular Sciences, 2022, 23, 9391.	4.1	13
1093	Real-world management patterns in <i>EGFR</i>-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. Future Oncology, 0, , .	2.4	0
1094	State-of-the-art combination treatment strategies for advanced stage nonâ€“small cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	8
1095	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology, 0, 12, .	2.8	4

#	ARTICLE	IF	CITATIONS
1096	EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases. <i>Journal of Neuro-Oncology</i> , 2022, 159, 675-684.	2.9	1
1097	Prognostic significance of TG/HDL-C and non-HDL-C/HDL-C ratios in patients with non-small cell lung cancer: a retrospective study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211172.	1.0	3
1100	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
1101	Lung Cancer in the Course of COPD-Emerging Problems Today. <i>Cancers</i> , 2022, 14, 3819.	3.7	3
1102	Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial. <i>Nature Medicine</i> , 2022, 28, 1640-1645.	30.7	83
1103	Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. <i>Clinical Lung Cancer</i> , 2022, 23, 643-658.	2.6	5
1104	Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study. <i>Current Oncology</i> , 2022, 29, 6125-6136.	2.2	1
1105	Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
1106	Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	13
1108	Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. <i>Neoplasia</i> , 2022, 32, 100832.	5.3	3
1109	Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. <i>Lung Cancer</i> , 2022, 172, 65-74.	2.0	5
1110	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. <i>ESMO Open</i> , 2022, 7, 100560.	4.5	1
1111	Multiple disciplinary team management of rare primary splenic malignancy: Two case reports. <i>World Journal of Clinical Cases</i> , 0, 10, 10535-10542.	0.8	2
1112	Primary lung carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT). <i>European Journal of Cancer</i> , 2022, 175, 19-30.	2.8	6
1113	EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. <i>Lung Cancer</i> , 2022, 173, 58-66.	2.0	5
1114	Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe. <i>Journal of Cancer Policy</i> , 2022, 34, 100362.	1.4	2
1115	Shashen-Maidong Decoction inhibited cancer growth under intermittent hypoxia conditions by suppressing oxidative stress and inflammation. <i>Journal of Ethnopharmacology</i> , 2022, 299, 115654.	4.1	3
1116	Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. <i>Cancer Control</i> , 2022, 29, 107327482211294.	1.8	0



#	ARTICLE	IF	CITATIONS
1117	Egfr Mutation Prevalence, Real-World Treatment Patterns, and Outcomes Among Patients with Resected, Early-Stage, Non-Small Cell Lung Cancer in Canada. SSRN Electronic Journal, 0, , .	0.4	0
1118	Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy. Therapeutic Advances in Medical Oncology, 2022, 14, .	3.2	10
1119	Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer. Clinical Cancer Research, 2023, 29, 316-323.	7.0	19
1120	Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms. Modern Pathology, 2022, 35, 1882-1887.	5.5	14
1121	Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study. British Journal of Clinical Pharmacology, 0, , .	2.4	0
1122	The Potential Application of Branch-PCR Assembled PTEN Gene Nanovector in Lung Cancer Gene Therapy. ChemBioChem, 2022, 23, .	2.6	5
1123	Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer—A Generating Hypothesis Study. Cancers, 2022, 14, 4770.	3.7	4
1124	Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. Diagnostics, 2022, 12, 2360.	2.6	0
1125	Prognostic Value of Combination of Controlling Nutritional Status and Tumor Marker in Patients with Radical Non-Small-Cell Lung Cancer. Disease Markers, 2022, 2022, 1-12.	1.3	1
1126	Drug-induced liver injury associated with dacomitinib: A case report. Frontiers in Oncology, 0, 12, .	2.8	1
1127	Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. British Journal of Cancer, 2022, 127, 2034-2042.	6.4	8
1128	Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study. Translational Lung Cancer Research, 2022, 11, 1796-1808.	2.8	1
1129	EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience. Journal of Thoracic Disease, 2022, 14, 3364-3375.	1.4	1
1130	Sublobar resection without staging and lymphadenectomy for 2% Non-Small Cell Lung Cancer is no adequate therapy. Surgical Oncology, 2022, 44, 101840.	1.6	2
1131	Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study. BMC Pulmonary Medicine, 2022, 22, .	2.0	2
1132	A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical and Translational Oncology, 2023, 25, 283-291.	2.4	2
1133	Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. Frontiers in Public Health, 0, 10, .	2.7	3
1134	Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	3

#	ARTICLE	IF	CITATIONS
1135	Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Nonâ€‘small Cell Lung Cancer. Cancer Research Communications, 2022, 2, 1174-1187.	1.7	3
1136	Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced nonâ€‘small cell lung cancer in Spain. Global & Regional Health Technology Assessment, 0, 9, 82-90.	0.1	0
1137	Adjuvant atezolizumab in Japanese patients with resected stage <scp>IBâ€‘IIA</scp> nonâ€‘small cell lung cancer (<scp>IMpower010</scp>). Cancer Science, 2022, 113, 4327-4338.	3.9	9
1138	Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma. OncoTargets and Therapy, 0, Volume 15, 981-989.	2.0	0
1139	Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC). Cancers, 2022, 14, 4633.	3.7	3
1140	A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma. CEN Case Reports, 0, , .	0.9	1
1141	Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastasesâ€‘a Single-Center Study in 190 Patients. JTO Clinical and Research Reports, 2022, 3, 100413.	1.1	1
1142	Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 1734-1738.	2.8	1
1143	Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis. Frontiers in Oncology, 0, 12, .	2.8	5
1144	Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study. Frontiers in Surgery, 0, 9, .	1.4	0
1145	Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. BioDrugs, 2022, 36, 749-760.	4.6	2
1146	Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. European Respiratory Journal, 2023, 61, 2201336.	6.7	8
1147	Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. Heliyon, 2022, 8, e10932.	3.2	7
1148	Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group. Cancer Treatment and Research Communications, 2022, , 100646.	1.7	0
1149	Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer, 2022, 173, 116-123.	2.0	2
1150	The role of metformin in the treatment of non-small cell lung cancer. Zdravstvena Zastita, 2022, 51, 32-53.	0.2	0
1151	Gene Variations of Chemokine and Chemokine Receptor CXCL12/CXCR4 in Lung Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2022, , .	1.2	1
1152	The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them. Cancer Drug Resistance (Alhambra, Calif ), 0, 5, 1016-24.	2.1	1

#	ARTICLE	IF	CITATIONS
1153	Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, 1-11.	5.2	4
1154	Protein tyrosine kinase 6 regulates activation of SRC kinase. Journal of Biological Chemistry, 2022, 298, 102584.	3.4	4
1157	Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)â€”A Single Center, Retrospective Observational Study. International Journal of Molecular Sciences, 2022, 23, 12511.	4.1	2
1159	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Current Oncology Reports, 2022, 24, 1801-1819.	4.0	7
1160	BRAF Inhibitors in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 4863.	3.7	4
1161	Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors. Frontiers in Oncology, 0, 12, .	2.8	8
1162	Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptorâ€”Mutated, <i>MET</i>-Amplified Nonâ€”Small Cell Lung Cancer: TATTON. Cancer Discovery, 2023, 13, 98-113.	9.4	35
1166	Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Targeted Oncology, 2022, 17, 727-733.	3.6	5
1167	Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Nonâ€”Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 2023, 41, 1200-1212.	1.6	75
1168	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Proteinâ€”Expressing Nonâ€”Small-Cell Lung Cancer. Journal of Clinical Oncology, 2023, 41, 1105-1115.	1.6	24
1169	Effects of spatial variation in dose delivery: what can we learn from radon-related lung cancer studies?. Radiation and Environmental Biophysics, 2022, 61, 561-577.	1.4	12
1170	Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer. Cells, 2022, 11, 3226.	4.1	0
1172	ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology, 2022, 180, 103847.	4.4	2
1173	Ultrasound-Guided Needle Aspiration Biopsy of Superficial Metastasis of Lung Cancer with and without Rapid On-Site Evaluation: A Randomized Trial. Cancers, 2022, 14, 5156.	3.7	1
1174	Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials. Cancers, 2022, 14, 5339.	3.7	5
1175	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Nonâ€”Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score â‰¥ 1% in the KEYNOTE-042 Study. Journal of Clinical Oncology, 2023, 41, 1986-1991.	1.6	47
1176	Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future. Diagnostics, 2022, 12, 2644.	2.6	20
1177	Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review. BMC Cancer, 2022, 22, .	2.6	5

#	ARTICLE	IF	CITATIONS
1178	Dose-Response Analysis Describes Particularly Rapid Repopulation of Non-Small Cell Lung Cancer during Concurrent Chemoradiotherapy. <i>Cancers</i> , 2022, 14, 4869.	3.7	0
1179	Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1197-1210.	2.4	3
1180	Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study. <i>Lung Cancer</i> , 2022, 174, 67-70.	2.0	3
1181	Radiation Therapy for Brain Metastases. <i>Medical Radiology</i> , 2022, , .	0.1	0
1182	Datele din lumea reală și studiile clinice pentru evaluarea eficacității noilor terapii oncologice. Rolul studiilor observaționale, cu exemplificare în cancerul pulmonar fără celule mici (NSCLC). <i>Oncolog-Hematolog Ro</i> , 2022, 3, 23.	0.0	0
1183	Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 707-720.	2.8	4
1184	Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy. <i>Cancer Management and Research</i> , 0, Volume 14, 3191-3202.	1.9	1
1185	TFG-Î <sup>2</sup> Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13780.	4.1	0
1186	Circulating tumor DNA as a novel prognostic indicator. <i>Nature Medicine</i> , 2022, 28, 2255-2256.	30.7	1
1187	KRAS in NSCLC: State of the Art and Future Perspectives. <i>Cancers</i> , 2022, 14, 5430.	3.7	18
1188	Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 174, 146-156.	2.0	13
1189	Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia. <i>Journal of Thoracic Oncology</i> , 2023, 18, 436-446.	1.1	15
1190	Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study. <i>Lung Cancer</i> , 2023, 175, 47-56.	2.0	1
1191	Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study. <i>Acta Oncologica</i> , 2022, 61, 1354-1361.	1.8	2
1192	Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. <i>ESMO Open</i> , 2022, 7, 100612.	4.5	3
1193	The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113959.	5.6	4
1194	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. <i>Annals of Oncology</i> , 2023, 34, 173-185.	1.2	8
1195	Green sensitive spectrofluorimetric determination of pemetrexed as antineoplastic drug: Application in pharmaceutical dosage forms and spiked human plasma. <i>Luminescence</i> , 2023, 38, 64-70.	2.9	1

#	ARTICLE	IF	CITATIONS
1196	Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer. <i>Translational Oncology</i> , 2023, 27, 101589.	3.7	7
1197	Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, .	1.0	0
1198	KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner. <i>Drug Resistance Updates</i> , 2023, 66, 100908.	14.4	13
1199	A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT). <i>Journal of Gastrointestinal Oncology</i> , 2022, .	1.4	0
1200	Patient-Derived Organoids as a Stem Cell Model to Study Lung Cancer. , 2022, , .		0
1201	Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer. <i>European Medical Journal Oncology</i> , 0, , 90-99.	0.0	0
1202	Sanguisorba officinalis L. suppresses non-small cell lung cancer via downregulating the PI3K/AKT/mTOR signaling pathway based on network pharmacology and experimental investigation. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
1203	Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 5810.	3.7	3
1204	Paraneoplastic Opsoclonus-Myoclonus Syndrome as a Rare Presentation of Small-Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.5	1
1205	Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
1206	Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. <i>Cells</i> , 2022, 11, 3826.	4.1	8
1207	Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population. <i>Pharmaceuticals</i> , 2022, 15, 1474.	3.8	1
1208	Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia. <i>Cancers</i> , 2022, 14, 5791.	3.7	0
1209	Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	1.9	0
1210	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.3	2
1211	Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4416-4426.	1.4	2
1212	Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	2.3	0
1213	Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14724.	4.1	4

#	ARTICLE	IF	CITATIONS
1214	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. Thoracic and Cardiovascular Surgeon, 0, , .	1.0	0
1215	The “new” oligometastatic disease state and associated therapies in non-small cell lung cancer: A narrative review. Journal of Surgical Oncology, 2023, 127, 282-287.	1.7	3
1216	Possible heart failure caused by osimertinib in a lung cancer patient. Journal of Oncology Pharmacy Practice, 2023, 29, 1015-1020.	0.9	1
1217	Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory. Journal of Clinical Pathology, 0, , jcp-2022-208625.	2.0	3
1218	New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2023, 25, 1252-1267.	2.4	5
1219	A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy. Cureus, 2022, , .	0.5	0
1220	EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives. European Medical Journal (Chelmsford, England), 0, , .	3.0	0
1221	Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial. Cancers, 2022, 14, 6074.	3.7	1
1222	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	2.8	1
1223	Case report: Liquid biopsy, the sooner the better?. Frontiers in Oncology, 0, 12, .	2.8	2
1224	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer With High Tumor Mutation Burden. JAMA Oncology, 2023, 9, 344.	7.1	13
1225	Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer. Thoracic Cancer, 2023, 14, 437-441.	1.9	4
1226	Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC. Journal of Thoracic Oncology, 2023, 18, 487-498.	1.1	14
1228	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	17.0	46
1229	Application of nnU-Net for Automatic Segmentation of Lung Lesions on CT Images and Its Implication for Radiomic Models. Journal of Clinical Medicine, 2022, 11, 7334.	2.4	5
1230	B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?. International Journal of Molecular Sciences, 2022, 23, 16077.	4.1	2
1231	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2023, 182, 103891.	4.4	6
1232	Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. BMJ Case Reports, 2022, 15, e252590.	0.5	1



#	ARTICLE	IF	CITATIONS
1233	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 228-246.	1.2	38
1234	Current treatment approaches for brain metastases in <i>ALK</i> / <i>ROS1</i> / <i>NTRK</i> -positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 29-41.	2.4	1
1235	Clinical Outcomes, Treatment and Testing Patterns in Patients with Advanced Non-Small Lung Cell Cancer with Epidermal Growth Factor Receptor Mutations: Results of the Romanian Cohort From a Multi-national Retrospective Chart Review (REFLECT). <i>Journal of Medical &amp; Radiation Oncology</i> , 2022, 2, 27-37.	0.0	0
1236	Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
1237	Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
1238	Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012â€“2018. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	0
1239	Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	1.5	0
1240	Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
1241	A Case of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer: Multi-Line Treatment and Resistance Mechanisms. <i>Cureus</i> , 2023, , .	0.5	0
1242	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2023, 15, 329.	3.7	8
1243	Dual inhibition of EGFRâ€“VEGF: An effective approach to the treatment of advanced nonâ€“small cell lung cancer with EGFR mutation (Review). <i>International Journal of Oncology</i> , 2023, 62, .	3.3	8
1245	Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Nonâ€“Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 814-831.	3.0	0
1246	Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1247	Insight into the relationships of structure and anti-tumor effects of Glucuronomannan oligosaccharides (Gx) and its derivatives on the A549 lung adenocarcinoma cells. <i>Algal Research</i> , 2023, 70, 102979.	4.6	0
1248	Mutational Profiling of Lung Cancer Using Next Generation Sequencing: A Malaysian Real-World Clinical Diagnostic Experience. <i>Journal of Molecular Pathology</i> , 2023, 4, 31-43.	1.2	2
1249	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	1.4	0
1250	Phase 1 study of DSâ€1205c combined with gefitinib for EGFR mutationâ€positive nonâ€small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	2.8	1
1251	Nintedanib-Î±Î²6 Integrin Ligand Conjugates Reduce TGFÎ²-Induced EMT in Human Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1475.	4.1	0

#	ARTICLE	IF	CITATIONS
1252	Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions. <i>ESMO Open</i> , 2023, 8, 100764.	4.5	0
1253	Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101423.	1.0	2
1254	Demystifying the Discussion of Sequencing Panel Size in Oncology Genetic Testing. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 68-77.	3.0	5
1255	The Mechanism of Quercetin in the Treatment of Lung Squamous Cell Carcinoma Based on a Protein-Protein Interaction Network. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-14.	1.2	0
1256	Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100457.	1.1	2
1257	Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. <i>Cancers</i> , 2023, 15, 185.	3.7	0
1258	Testing for <i>EGFR</i> Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2023, 9, 261.	7.1	4
1259	Impact of Type 2 Diabetes Mellitus on the Prognosis of Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 321.	2.4	2
1260	The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
1261	Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. <i>Clinical Lung Cancer</i> , 2023, , .	2.6	2
1262	Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. <i>Cancers</i> , 2023, 15, 841.	3.7	15
1263	MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. <i>Cancers</i> , 2023, 15, 710.	3.7	11
1264	Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment. <i>Cancers</i> , 2023, 15, 636.	3.7	3
1265	Assessment of survival outcomes among lung cancer patients at the National and Referral Hospital in Kenya. <i>Cancer Medicine</i> , 2023, 12, 9194-9201.	2.8	1
1266	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2023, 43, 713-724.	1.1	4
1267	Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection – A systematic review. <i>Lung Cancer</i> , 2023, 178, 75-86.	2.0	1
1268	When tissue is not the only issue: Poorly differentiated lung squamous-cell carcinoma with adrenal, costochondral, and cardiac metastases – case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1269	A real-world study of second or later-line osimertinib in patients with <i>EGFR</i> T790M-positive NSCLC: the final ASTRIS data. <i>Future Oncology</i> , 2023, 19, 61-75.	2.4	1

#	ARTICLE	IF	CITATIONS
1270	Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1≥50%. Cancer Immunology, Immunotherapy, 2023, 72, 1881-1890.	4.2	4
1272	Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORC1426. Translational Cancer Research, 2023, .	1.0	0
1273	High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts. Translational Lung Cancer Research, 2023, .	2.8	0
1274	Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives. Translational Lung Cancer Research, 2023, 12, 824-836.	2.8	2
1275	Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2023, 12, 1266.	2.4	1
1276	The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <i>MET</i> Alterations. Molecular Cancer Therapeutics, 2023, 22, 833-843.	4.1	4
1277	Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells. Oncology Letters, 2023, 25, .	1.8	3
1278	Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational New Drugs, 2023, 41, 306-316.	2.6	3
1279	Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC. Journal of Thoracic Oncology, 2023, 18, 896-906.	1.1	3
1280	Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188869.	7.4	1
1281	Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. Analytical Biochemistry, 2023, 669, 115115.	2.4	1
1282	Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer, 2023, 179, 107190.	2.0	6
1283	Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective. Cancer Treatment Reviews, 2023, 116, 102544.	7.7	2
1284	Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report. Respiratory Medicine and Research, 2023, 83, 101000.	0.6	1
1285	Immunotherapy in Small Cell Lung Cancer. European Medical Journal (Chelmsford, England), 0, , 43-53.	3.0	2
1286	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European Journal of Cancer, 2023, 183, 38-48.	2.8	8
1287	First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. , 2023, 11, e006127.		14
1288	Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer, 2023, 178, 116-122.	2.0	7

#	ARTICLE	IF	CITATIONS
1289	Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy, 2023, 15, 293-309.	2.0	2
1290	Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss Medical Weekly, 2023, 153, 40039.	1.6	0
1291	<scp>Firstâ€line</scp> <i>nab</i>â€paclitaxel plus carboplatin for patients with advanced nonâ€small cell lung cancer: Final results of the <scp>NEPTUN</scp> study. International Journal of Cancer, 2023, 153, 141-152.	5.1	1
1292	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. Scientific Reports, 2023, 13, .	3.3	1
1293	Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. PLoS ONE, 2023, 18, e0277708.	2.5	3
1294	Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases. Journal of Clinical Medicine, 2023, 12, 1411.	2.4	1
1295	Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts?. , 2023, , .		0
1296	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 3618.	4.1	6
1297	Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?. ESMO Open, 2023, 8, 100879.	4.5	2
1298	A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced nonâ€small cell lung cancer patients. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1714-1725.	2.5	3
1299	Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opinion on Biological Therapy, 2023, 23, 261-268.	3.1	1
1300	Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing. Neoplasia, 2023, 38, 100884.	5.3	3
1301	Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping. Value in Health, 2023, 26, 1155-1163.	0.3	1
1302	SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. , 2023, 11, e006055.		8
1303	A global analysis of the value of precision medicine in oncology â€“ The case of non-small cell lung cancer. Frontiers in Medicine, 0, 10, .	2.6	0
1304	Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. General Thoracic and Cardiovascular Surgery, 0, , .	0.9	0
1306	Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Medicine, 2023, 21, .	5.5	7
1307	Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases. JTO Clinical and Research Reports, 2023, 4, 100483.	1.1	0

#	ARTICLE	IF	CITATIONS
1308	Liquid Biopsies in Lung Cancer. <i>Cancers</i> , 2023, 15, 1430.	3.7	7
1309	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). <i>Lung Cancer</i> , 2023, 178, 191-197.	2.0	3
1310	Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-1 ligand 1 inhibitors in non-small cell lung cancer. <i>Cancer</i> , 2023, 129, 1319-1350.	4.1	3
1311	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	12.8	38
1312	Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. <i>Nature Communications</i> , 2023, 14, .	12.8	24
1313	Liquid Biopsy: A New Strategy for Future Directions in Lung Cancer Treatment. , 0, , .		0
1314	Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with <i>ALK</i> -positive non-small cell lung cancer. <i>Cancer Science</i> , 2023, 114, 2560-2568.	3.9	2
1315	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. <i>ESMO Open</i> , 2023, 8, 101160.	4.5	3
1316	Artificial Intelligence for Cardiothoracic Imaging: Overview of Current and Emerging Applications. <i>Seminars in Roentgenology</i> , 2023, 58, 184-195.	0.6	1
1317	Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study. <i>Cancers</i> , 2023, 15, 1581.	3.7	0
1318	<i>Circular RNA</i> <i>DLG1</i> (has_circ_0068706) functions as an oncogene in nonsmall cell lung cancer through regulating <i>AKT</i> / <i>mTOR</i> signaling and direct binding to <i>miR-144</i> . <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 446-457.	1.9	1
1320	Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 679-690.	4.1	0
1321	The Surgical Management of Lung Neuroendocrine Neoplasms. <i>Cancers</i> , 2023, 15, 1695.	3.7	4
1322	Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 594-614.	2.8	6
1323	Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy. <i>Cancer</i> , 2023, 129, 1662-1671.	4.1	2
1324	Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100499.	1.1	1
1325	Association of smoking with the survival of patients with brain metastasis of lung cancer. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
1327	Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2355.	2.4	1

#	ARTICLE	IF	CITATIONS
1328	CT radiomics model combined with clinical and radiographic features for discriminating peripheral small cell lung cancer from peripheral lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
1329	RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+) Tj ETQq1 1 0,784314 rgBT /Overd	2.6	0
1330	Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Non-Small Cell Lung Cancer. <i>Chromatography</i> , 2023, , .	1.7	1
1331	The application of pancreatic cancer organoids for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 429-444.	5.0	0
1332	Combi-TED: a new trial testing Tedopi <sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. <i>Future Oncology</i> , 2022, 18, 4457-4464.	2.4	1
1334	Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1968.	3.7	7
1335	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	14
1336	Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions. <i>Cancers</i> , 2023, 15, 2081.	3.7	5
1337	Incidence of bone metastases and skeletal related events in patients with epidermal growth factor receptor mutated non-small cell lung cancer treated with osimertinib. <i>JTO Clinical and Research Reports</i> , 2023, , 100513.	1.1	0
1339	Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions. <i>OncoTargets and Therapy</i> , 0, Volume 16, 249-259.	2.0	2
1340	Case reports of patients with ALK-positive NSCLC and brain metastases. <i>Onkologie (Czech Republic)</i> , 2023, 17, 57-61.	0.1	0
1341	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. <i>Cancer Cell International</i> , 2023, 23, .	4.1	24
1342	Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer. <i>Cancers</i> , 2023, 15, 2244.	3.7	1
1343	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2297.	3.7	3
1344	Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. <i>Pharmaceutics</i> , 2023, 15, 1252.	4.5	7
1345	Emerging evidence and treatment paradigm of non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	17
1346	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceutics</i> , 2023, 16, 614.	3.8	18
1347	Ginsenoside Rh2 attenuates the progression of non-small cell lung cancer by sponging miR-285p and inactivating Wnt/ $\beta$ -catenin signaling. <i>Cancer Medicine</i> , 2023, 12, 12653-12667.	2.8	2



#	ARTICLE	IF	CITATIONS
1348	Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1350	Deep learning to estimate lung disease mortality from chest radiographs. <i>Nature Communications</i> , 2023, 14, .	12.8	5
1351	Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2023, 13, 393-412.	2.1	12
1352	Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study. <i>Journal of Geriatric Oncology</i> , 2023, , 101506.	1.0	1
1353	Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting. <i>Journal of Molecular Pathology</i> , 2023, 4, 81-88.	1.2	0
1354	A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer. <i>ESMO Open</i> , 2023, 8, 101173.	4.5	1
1355	Correlation analysis of lung mucosa-colonizing bacteria with clinical features reveals metastasis-associated bacterial community structure in non-small cell lung cancer patients. <i>Respiratory Research</i> , 2023, 24, .	3.6	1
1356	High tumor burden in patients with non-small-cell lung cancer: a Delphi survey among Spanish oncologists. <i>Future Oncology</i> , 2023, 19, 991-1002.	2.4	0
1357	The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib. <i>OncoTargets and Therapy</i> , 0, Volume 16, 317-326.	2.0	0
1358	Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study. <i>Advances in Therapy</i> , 2023, 40, 3135-3168.	2.9	0
1359	Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100532.	1.1	3
1360	Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321. <i>Cancer Medicine</i> , 0, , .	2.8	0
1361	Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. <i>Current Oncology</i> , 2023, 30, 5299-5308.	2.2	0
1362	Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond. <i>Lung Cancer</i> , 2023, 181, 107260.	2.0	1
1363	Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. <i>Tumor Biology</i> , 2023, , 1-14.	1.8	1
1364	Survival with lung cancer in Finland has not improved during 2007-2019: a single center retrospective population-based real-world study. <i>Acta Oncologica</i> , 2023, 62, 571-578.	1.8	0
1365	Relation of osteopontin expression to tumor-associated macrophages-derived transforming growth factor beta 1 expression in non-small cell lung carcinoma. <i>Journal of Microscopy and Ultrastructure</i> , 2023, .	0.4	0
1366	Application of Monocyte-to-Albumin Ratio and Neutrophil Percentage-to-Hemoglobin Ratio on Distinguishing Non-Small Cell Lung Cancer Patients from Healthy Subjects. <i>International Journal of General Medicine</i> , 0, Volume 16, 2175-2185.	1.8	0

#	ARTICLE	IF	CITATIONS
1367	Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i> <sup>V600</sup> -Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3700-3711.	1.6	8
1368	The molecular characteristics of non-small cell lung cancer in the Northern Territory's Top End. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	1.1	2
1369	Treatment of unresectable stage III NSCLC: Real world cohort study and literature review. <i>Cancer Treatment and Research Communications</i> , 2023, 36, 100727.	1.7	0
1370	Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects. <i>Cancer Treatment and Research Communications</i> , 2023, 36, 100725.	1.7	0
1371	Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	4
1372	Construction of the XGBoost model for early lung cancer prediction based on metabolic indices. <i>BMC Medical Informatics and Decision Making</i> , 2023, 23, .	3.0	6
1373	Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001492.	3.0	2
1374	High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer. <i>Biomolecules</i> , 2023, 13, 991.	4.0	1
1375	Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. <i>Targeted Oncology</i> , 0, , .	3.6	0
1376	Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
1377	Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	1
1378	NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC. <i>Lung Cancer</i> , 2023, 182, 107283.	2.0	1
1379	Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma. <i>BMJ Case Reports</i> , 2023, 16, e254268.	0.5	0
1380	Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. <i>ESMO Open</i> , 2023, 8, 101587.	4.5	6
1381	Overexpression of <i>SMAD7</i> improves the function of <i>EGFR</i> -targeted human <i>CAR-T</i> cells against non-small-cell lung cancer. <i>Respirology</i> , 2023, 28, 869-880.	2.3	2
1382	Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2024, 148, e18-e24.	2.5	0
1383	Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. <i>Journal of Thoracic Oncology</i> , 2023, 18, 1594-1606.	1.1	1
1384	Survival Outcomes in Advanced Non-Small Cell Lung Cancer in a Cancer Center in Medellin - Colombia. <i>CES Medicina</i> , 2023, 37, 44-57.	0.1	0

#	ARTICLE	IF	CITATIONS
1385	Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	2
1386	Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer, 2023, 23, .	2.6	2
1387	KRAS G12C Mutant Non-“Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Clinical Lung Cancer, 2023, 24, 507-518.	2.6	3
1388	Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2023, 4, 100525.	1.1	1
1389	Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panel. Pulmonology, 2024, 30, 4-7.	2.1	1
1390	Integrated Bioinformatics Approach for Disclosing Autophagy Pathway as a Therapeutic Target in Advanced KRAS Mutated/Positive Lung Adenocarcinoma. Open Bioinformatics Journal, 2023, 16, .	1.0	2
1391	Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies. International Journal of Molecular Sciences, 2023, 24, 10558.	4.1	0
1392	The Choosing Wisely Oncology Canada Cancer List: An Update. Journal of Cancer Policy, 2023, 37, 100431.	1.4	0
1393	Characterization of the immune environment in pregnancy-associated breast cancer. Future Oncology, 2023, 19, 1073-1089.	2.4	0
1394	Gefitinib-induced Myositis: A Novel Case Report. Yakugaku Zasshi, 2023, 143, 617-620.	0.2	1
1395	Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors. Lung Cancer, 2023, 182, 107290.	2.0	1
1396	Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches. Pathology Research and Practice, 2023, 248, 154660.	2.3	1
1397	Persistent increase and improved survival of stage I lung cancer based on a large-scale real-world sample of 26,226 cases. Chinese Medical Journal, 0, , .	2.3	0
1398	Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study. Frontiers in Oncology, 0, 13, .	2.8	0
1399	External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data. Cancer Chemotherapy and Pharmacology, 2023, 92, 205-210.	2.3	0
1400	First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet, The, 2023, 402, 451-463.	13.7	20
1401	A Cross-Talk about Radioresistance in Lung Cancer-“How to Improve Radiosensitivity According to Chinese Medicine and Medicaments That Commonly Occur in Pharmacies. International Journal of Molecular Sciences, 2023, 24, 11206.	4.1	2
1402	Establishment of a prognostic risk prediction model for non-small cell lung cancer patients with brain metastases: a retrospective study. PeerJ, 0, 11, e15678.	2.0	3

#	ARTICLE	IF	CITATIONS
1403	CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer. <i>Pharmacological Research</i> , 2023, 194, 106850.	7.1	4
1404	Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer. <i>Cancers</i> , 2023, 15, 3578.	3.7	0
1405	Management of limited stage Hodgkin lymphoma. , 0, , .		0
1406	Spatially Resolved Proteomic and Transcriptomic Profiling of Anaplastic Lymphoma Kinase-Rearranged Pulmonary Adenocarcinomas Reveals Key Players in Inter- and Intratumoral Heterogeneity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11369.	4.1	0
1407	Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 12459-12468.	2.5	0
1408	Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC. <i>Lung Cancer</i> , 2023, 183, 107308.	2.0	0
1409	Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administrationâ€”induced nephropathy. <i>British Journal of Clinical Pharmacology</i> , 0, , .	2.4	0
1410	Integrative analysis illustrates the role of PCDH7 in lung cancer development, cisplatin resistance, and immunotherapy resistance: an underlying target. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1411	Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer. , 2023, , .		0
1412	A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine â€œFlareâ€”on Positron Emission Tomography. <i>Cancers</i> , 2023, 15, 3718.	3.7	0
1413	Heterogeneity of Glycolytic Phenotype Determined by 18F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2023, 13, 2448.	2.6	2
1415	Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11887.	4.1	7
1416	Efficient Lung Cancer Molecular Diagnostics by Combining Next Generation Sequencing with Reflex Idylla Genefusion Assay Testing. <i>Genes</i> , 2023, 14, 1551.	2.4	0
1417	Molecular testing in non-small cell lung cancer: A consensus recommendation. <i>Annals of the Academy of Medicine, Singapore</i> , 2023, 52, 364-373.	0.4	0
1418	Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	3.0	3
1419	Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. <i>Journal of Thoracic Oncology</i> , 2023, 18, 1581-1593.	1.1	6
1421	Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. <i>Tumor Biology</i> , 2023, , 1-13.	1.8	3
1422	Machine-Learning-Aided Prediction of Brain Metastases Development in Nonâ€”Small-Cell Lung Cancers. <i>Clinical Lung Cancer</i> , 2023, 24, e311-e322.	2.6	1

#	ARTICLE	IF	CITATIONS
1423	Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis. Lung Cancer, 2023, 184, 107321.	2.0	2
1424	Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis. Lung Cancer, 2023, 184, 107319.	2.0	0
1425	Genomic alterations as independent prognostic factors to predict the type of lung cancer recurrence. Gene, 2023, 885, 147690.	2.2	1
1426	Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity. Frontiers in Oncology, 0, 13, .	2.8	2
1427	Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced/metastatic non-small cell lung cancer in the <scp>EU5</scp>. Thoracic Cancer, 2023, 14, 2846-2858.	1.9	1
1428	Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022) Tj ETQq1 1 0.784314 rgBT /Overbo	7.4	0
1429	Bio-evaluation of the 2-nitrochalcones as potential anti-lung cancer agents, inducers of apoptosis and inhibitors of protein kinase (VEGFR-2). Medicinal Chemistry Research, 2023, 32, 2380-2393.	2.4	2
1430	Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients. International Journal of Molecular Sciences, 2023, 24, 13390.	4.1	2
1432	Clinical Applications of Endobronchial Ultrasound (EBUS) Scope: Challenges and Opportunities. Diagnostics, 2023, 13, 2565.	2.6	1
1433	Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis. Cancers, 2023, 15, 4433.	3.7	4
1434	Efficacy and safety of reduced-dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A <scp>real-world</scp> observational study. Cancer Medicine, 2023, 12, 18679-18690.	2.8	1
1435	Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 573-594.	6.1	4
1436	Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer. Journal of Translational Medicine, 2023, 21, .	4.4	0
1437	Design, synthesis, computational study and cytotoxic evaluation of some new quinazoline derivatives containing pyrimidine moiety. Scientific Reports, 2023, 13, .	3.3	3
1438	Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. Lung Cancer, 2023, 183, 107318.	2.0	1
1439	Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. Clinical and Translational Oncology, 2023, 25, 3139-3151.	2.4	1
1440	Defining Oligometastatic Bladder Cancer: A Systematic Review. European Urology Open Science, 2023, 55, 28-37.	0.4	1
1441	Early acquired resistance to EGFR-TKIs in lung adenocarcinomas before radiographic advanced identified by CT radiomic delta model based on two central studies. Scientific Reports, 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
1442	Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer. Journal of Functional Biomaterials, 2023, 14, 466.	4.4	0
1443	Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	2
1444	Thirty-Day Complications, Unplanned Hospital Encounters, and Mortality after Endosonography and/or Guided Bronchoscopy: A Prospective Study. Cancers, 2023, 15, 4531.	3.7	0
1445	The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer, 2023, 184, 107356.	2.0	1
1446	Clinical Trial and Real-World Outcomes of Metastatic Non-Small Cell Lung Cancer Patients in the Post Platinum-Based Chemotherapy Failure Setting. JTO Clinical and Research Reports, 2023, , 100579.	1.1	0
1447	Do patient characteristics affect <scp>EGFR</scp> tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line <scp>EGFR-TKIs</scp>. Thoracic Cancer, 2023, 14, 3208-3216.	1.9	0
1448	Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation. Scientific Reports, 2023, 13, .	3.3	1
1450	What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review. Expert Review of Respiratory Medicine, 2023, 17, 787-803.	2.5	0
1451	CT-based radiomic phenotypes of lung adenocarcinoma: a preliminary comparative analysis with targeted next-generation sequencing. Frontiers in Medicine, 0, 10, .	2.6	0
1452	Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Become the Standard of Care. Journal of Thoracic Oncology, 2023, 18, 986-989.	1.1	2
1453	National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. Lancet Oncology, The, 2023, 24, e344-e354.	10.7	7
1454	Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026. Future Oncology, 0, , .	2.4	0
1455	Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150. Tumor Biology, 2023, , 1-14.	1.8	1
1456	Implementing precision oncology for sarcoma patients: the CCCLM molecular tumor board experience. Journal of Cancer Research and Clinical Oncology, 2023, 149, 13973-13983.	2.5	1
1457	Adult attachment in couples facing stage IV lung cancer: associations with patient quality-of-life outcomes and sense of life completion. Journal of Psychosocial Oncology Research and Practice, 2023, 5, .	0.5	0
1458	Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies. Discover Oncology, 2023, 14, .	2.1	0
1459	Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2. JCI Insight, 2023, 8, .	5.0	1
1460	Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Annals of Oncology, 2023, 34, 920-933.	1.2	8



#	ARTICLE	IF	CITATIONS
1461	Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. <i>ESMO Open</i> , 2023, 8, 101628.	4.5	3
1463	Role of multiple dual-phase 18F-FDG PET/CT metabolic parameters in differentiating adenocarcinomas from squamous cell carcinomas of the lung. <i>Heliyon</i> , 2023, 9, e20180.	3.2	0
1464	Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naïve patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L). <i>BMC Cancer</i> , 2023, 23, .	2.6	0
1465	Optimization of Tissue Handling and Processing in the Era of Precision Medicine: A Practical Recommendation from a Multidisciplinary Panel of Indian Experts. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.2	0
1466	Evaluation of Patients with Lung Cancer. , 2023, , 1-18.		0
1467	Background of the need for targeted therapy options and platinum-based therapy responses in EGFR and ALK-mutated lung adenocarcinoma. <i>Turkish Journal of Clinics and Laboratory</i> , 2023, 14, 645-650.	0.4	0
1468	Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 1574.	7.1	7
1469	PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study. <i>Cancers</i> , 2023, 15, 4822.	3.7	1
1470	A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, , .	1.3	0
1471	The predictive value of 18F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy. <i>Lung Cancer</i> , 2023, 186, 107389.	2.0	0
1472	Efficacy and safety of Xiao-ai-ping injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e35483.	1.0	0
1473	Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1478	Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1480	Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. <i>Oncology</i> , 2024, 102, 30-42.	1.9	0
1481	CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. <i>Tumor Biology</i> , 2023, , 1-13.	1.8	1
1482	Co-occurrence of lung adenocarcinoma and pulmonary fibrosis in a patient: A comprehensive case study and review of existing literature on the successful utilization of nintedanib. <i>Pharmacia</i> , 2023, 70, 1127-1134.	1.2	0
1483	A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study). <i>Cancers</i> , 2023, 15, 4999.	3.7	1
1484	Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0

#	ARTICLE	IF	CITATIONS
1485	Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays. <i>Cancers</i> , 2023, 15, 5024.	3.7	1
1486	Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC. <i>PLoS ONE</i> , 2023, 18, e0292307.	2.5	0
1487	The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1488	Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators. <i>Targeted Oncology</i> , 0, , .	3.6	0
1489	Detection of Tumor DNA in Bronchoscopic Fluids in Peripheral NSCLC: A Proof-of-Concept Study. <i>JTO Clinical and Research Reports</i> , 2024, 5, 100596.	1.1	0
1490	A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2024, 19, 465-475.	1.1	2
1491	Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2023, 15, 5125.	3.7	1
1492	Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. , 2023, 11, e007047.		1
1493	Technical Validation of a Fully Integrated NGS Platform in the Real-World Practice of Italian Referral Institutions. <i>Journal of Molecular Pathology</i> , 2023, 4, 259-274.	1.2	0
1494	Lung Cancer Staging: Imaging and Potential Pitfalls. <i>Diagnostics</i> , 2023, 13, 3359.	2.6	1
1495	Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials. <i>Cancers</i> , 2023, 15, 5234.	3.7	0
1496	Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1497	A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	0
1498	Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review. <i>Medicina (Lithuania)</i> , 2023, 59, 2144.	2.0	0
1499	Correlation of Short Leukocyte Telomeres and Oxidative Stress with the Presence and Severity of Lung Cancer Explored by Principal Component Analysis. <i>Folia Biologica</i> , 2023, 69, 59-68.	0.6	0
1500	ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases. <i>Radiotherapy and Oncology</i> , 2024, 190, 109966.	0.6	0
1501	Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. <i>Cancer Management and Research</i> , 0, Volume 15, 1251-1262.	1.9	0
1502	Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. <i>Lung Cancer</i> , 2024, 187, 107414.	2.0	2

#	ARTICLE	IF	CITATIONS
1503	Efficacy and safety of the proposed bevacizumab biosimilar <scp>BAT1706</scp> compared with reference bevacizumab in patients with advanced nonsquamous nonâ€small cell lung cancer: A randomized, doubleâ€blind, phase <scp>III</scp> study. Cancer Medicine, 2023, 12, 20847-20863.	2.8	0
1504	Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications. Molecular Oncology, 2024, 18, 453-470.	4.6	0
1505	A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. BMC Cancer, 2023, 23, .	2.6	0
1507	On-cloud decision-support system for non-small cell lung cancer histology characterization from thorax computed tomography scans. Computerized Medical Imaging and Graphics, 2023, 110, 102310.	5.8	0
1508	Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. Nature Communications, 2023, 14, .	12.8	1
1509	Investigating Common Mutations in Exon 20 and 21 of EGFR Gene in Lung Cancer Tumor Tissue of NSCLC Type. Gene, Cell and Tissue, 2023, 11, .	0.2	0
1510	Development and Validation of a Machine Learningâ€Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective Case Control Study. Academic Radiology, 2023, , .	2.5	0
1511	Molecular diagnostics tailoring personalized cancer therapyâ€an oncologistâ€™s view. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2024, 484, 169-179.	2.8	1
1512	Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study. BMJ Open, 2023, 13, e076715.	1.9	0
1513	Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer, 2024, 187, 107427.	2.0	1
1515	Genomic Landscape and Actionable Mutations of Brain Metastases derived from Non-Small Cell Lung Cancer: a systematic review. Neuro-Oncology Advances, 0, , .	0.7	0
1516	Prognosis of patients with recurrent nonsmall cell lung cancer who received the best supportive care alone. Current Problems in Surgery, 2024, 61, 101429.	1.1	0
1517	The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treatment Reviews, 2024, 122, 102664.	7.7	2
1518	Longitudinal Circulating Tumor <scp>DNA</scp> Modeling to Predict Disease Progression in Firstâ€Line Mutant Epidermal Growth Factor Receptor <scp>Nonâ€small</scp> Cell Lung Cancer. Clinical Pharmacology and Therapeutics, 2024, 115, 349-360.	4.7	0
1519	Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis. Medicine (United States), 2023, 102, e36084.	1.0	1
1520	Kristen rat sarcoma virus (<scp><i>KRAS</i></scp>) <scp>G12Fâ€positive nonâ€small</scp> cell lung cancer mimicking <scp><i>KRAS</i></scp> G12C</scp> positivity: A case report. Thoracic Cancer, 0, , .	1.9	0
1521	Clonal Neoantigen: Emerging â€Mechanism-basedâ€Biomarker of Immunotherapy Response. Cancers, 2023, 15, 5616.	3.7	0
1522	Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonâ€Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. Journal of Clinical Oncology, 2024, 42, 192-204.	1.6	3

#	ARTICLE	IF	CITATIONS
1523	Efficacy and safety of iruplinalkib (WXâ€™0593) on nonâ€™small cell lung cancer with <i>SPECC1Lâ€™ALK</i> fusion: A case report. Experimental and Therapeutic Medicine, 2023, 27, .	1.8	0
1524	Superior Effectiveness of PDâ€™1 Inhibitor Plus Chemotherapy versus Bevacizumab Plus Chemotherapy as Firstâ€™Line Treatment for Nonâ€™Small Cell Lung Cancer with Brain Metastases. Advanced Therapeutics, 2024, 7, .	3.2	0
1525	A scenarioâ€™drafting study to explore potential future implementation pathways of circulating tumor <scp>DNA</scp> testing in oncology. Molecular Oncology, 0, , .	4.6	0
1526	Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma. Namâ€™k Kemal Tâ€™p Dergisi, 2023, 11, 385-394.	0.0	0
1527	Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre. ESMO Open, 2023, 8, 102197.	4.5	0
1530	Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Nonâ€™small-cell Lung Cancer. Clinical Lung Cancer, 2023, , .	2.6	0
1531	Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 1182-1187.	0.8	0
1532	Circ-NUP98 Promotes Lung Adenocarcinoma Development Through Regulating CBX1 by miR-188-3p. Biochemical Genetics, 0, , .	1.7	0
1533	From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics, 2024, 14, 48.	2.6	1
1534	H2S-Synthesizing Enzymes Are Putative Determinants in Lung Cancer Management toward Personalized Medicine. Antioxidants, 2024, 13, 51.	5.1	0
1535	Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer, 2024, 189, 107451.	2.0	0
1536	Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer. British Journal of Cancer, 2024, 130, 682-693.	6.4	0
1537	EBUS-guided cryobiopsy in the diagnosis of thoracic disorders. Pulmonology, 2024, , .	2.1	0
1538	Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing. International Journal of Clinical Oncology, 2024, 29, 96-102.	2.2	1
1539	Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study. Aging, 0, , .	3.1	0
1540	Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Frontiers in Oncology, 0, 13, .	2.8	0
1541	The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Pharmacology, 0, 15, .	3.5	0
1542	Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report. Frontiers in Oncology, 0, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
1543	Intraoperative near-infrared fluorescence imaging of peripheral lung tumors. Khirurgiya, 2024, , 79.	0.2	0
1544	Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by <i>EGFR</i> mutation type. Journal of Medical Economics, 2024, 27, 219-229.	2.1	0
1545	Progress in Immunotherapy of Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2024, 14, 1445-1452.	0.0	0
1546	Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic Cancer, 2024, 15, 529-537.	1.9	0
1547	Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
1548	Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance. , 2024, 2, 42-47.		0
1549	Italian position paper ( <i>SIPMO-SICMF</i> ) on medication-related osteonecrosis of the jaw ( <i>MRONJ</i> ). Oral Diseases, 0, , .	3.0	1
1550	Transcriptomic Profiling for Prognostic Biomarkers in Early-Stage Squamous Cell Lung Cancer (SqCLC). Cancers, 2024, 16, 720.	3.7	0
1551	Design, synthesis and evaluation of the 2-hydroxy-3-iodo-5-nitrochalcones for cytotoxicity (MCF-7) Tj ETQqO 0 0 rgBT /Overl... 2024, 1305, 137785.	3.6	0
1553	Molecular analysis of endobronchial ultrasound needle aspirates in patients with non-small cell lung cancer: Results from the SCOPE database. Cytopathology, 2024, 35, 378-382.	0.7	0
1554	METnet: A novel deep learning model predicting MET dysregulation in non-small-cell lung cancer on computed tomography images. Computers in Biology and Medicine, 2024, 171, 108136.	7.0	0
1556	Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion. BMC Pulmonary Medicine, 2024, 24, .	2.0	0
1557	Is there a prognostic difference among stage I lung adenocarcinoma patients with different <i>BRAF</i> mutation status?. Thoracic Cancer, 2024, 15, 715-721.	1.9	0
1558	Precision Targeting of Non-Small Cell Lung Cancer: Identifying Optimal Drug Targets and FDA-Approved Combinations for Enhanced Therapeutic Efficacy. , 2023, , .		0
1559	Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review. Cancers, 2024, 16, 995.	3.7	0
1560	Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Regional Health - Europe, The, 2024, 38, 100838.	5.6	0
1561	Cutting-Edge Therapies for Lung Cancer. Cells, 2024, 13, 436.	4.1	0
1562	SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases. Clinical and Translational Oncology, 0, , .	2.4	0

#	ARTICLE	IF	CITATIONS
1563	Metronomic Chemotherapy in Elderly Patients. Current Oncology Reports, 2024, 26, 359-376.	4.0	0
1564	Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis. Lung Cancer Management, 2024, 13, .	1.5	0
1565	Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK. Targeted Oncology, 2024, 19, 191-201.	3.6	0
1566	The mighty minions of non-small-cell lung cancer: EGFR, ALK, and ROS1. Cancer Research Statistics and Treatment, 2024, 7, 105-106.	0.6	0
1567	Genome-scale CRISPR-Cas9 screen identifies <i>PAICS</i> as a therapeutic target for <i>EGFR</i> wild-type non-small cell lung cancer. MedComm, 2024, 5, .	7.2	0
1568	KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. Cell Reports Medicine, 2024, 5, 101470.	6.5	0
1570	Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncology, The, 2024, 25, 439-454.	10.7	0
1571	Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects. Cancer Chemotherapy and Pharmacology, 0, , .	2.3	0